

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1240</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 20419</b>	International filing date (day/month/year) <b>07/09/1999</b>	(Earliest) Priority Date (day/month/year) <b>08/09/1998</b>
Applicant <b>E. I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

## 4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

## 5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

## 6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

**THIS PAGE BLANK (USPTO)**

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/20419

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/10 C12N15/29 C12N15/54 C12N15/70 C12N15/80

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	QIAN ET AL: "Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control" PLANT CELL, vol. 8, 1996, page 2381-2394 XP002090873 ROCKVILLE US ISSN: 1040-4651 page 2390 -page 2392	1,2,4, 6-8,10, 11,13,14
A	---	22, 24-26,29
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 April 2000

Date of mailing of the international search report

15.5.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

**THIS PAGE BLANK (USPTO)**

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YANG Z ET AL.: "PROTEIN FARNESYLTRANSFERASE IN PLANTS 1 MOLECULAR CLONING AND EXPRESSION OF A HOMOLOG OF THE BETA SUBUNIT FROM THE GARDEN PEA" PLANT PHYSIOLOGY, vol. 101, no. 2, 1993, page 667-674 XP000647522 ROCKVILLE US ISSN: 0032-0889 cited in the application abstract; figure 2</p>	1-5, 22, 30
A	---	22, 31
A	<p>CUTLER S. ET AL.: "A protein farnesyl transferase involved in abscisic acid signal transduction in arabidopsis" SCIENCE, vol. 273, August 1996 (1996-08), page 1239-1241 XP002090871 WASHINGTON US ISSN: 0036-8075</p>	1
A	<p>YALOVSKY S. ET AL.: "Plant farnesyl transferase can restore yeast ras signaling and mating" MOLECULAR AND CELLULAR BIOLOGY., vol. 17, no. 4, 1997, pages 1986-1994, XP000864327 WASHINGTON., US ISSN: 0270-7306 abstract</p>	1-5, 22, 27, 29
A	<p>HATA S. ET AL.: "cDNA cloning of squalene synthase genes from mono- and dicotyledonous plants, and expression of the gene in rice." PLANT AND CELL PHYSIOLOGY, vol. 38, no. 12, 1997, pages 1409-1413, XP000864329 abstract</p>	1
A	<p>MERLOT ET AL: "Genetic analysis of abscisic acid signal transduction" PLANT PHYSIOLOGY, vol. 114, 1997, page 751-757 XP002090872 ROCKVILLE US the whole document</p>	1
A	<p>SKOCZYLAS E. ET AL.: "Protein farnesyltransferase in plants" BIOCHIMIE, vol. 78, no. 2, 1996, pages 139-143, XP000864561 page 141, paragraph 2; figure 2</p>	1-5, 14, 22, 27

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/20419

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 2  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-22 partly and 23, 28 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a corn farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 1 or SEQ.ID.NO: 11.

2. Claims: 1-22 partly and 24, 29 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a rice farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 3 or SEQ.ID.NO: 13.

3. Claims: 1-22 partly and 25, 26, 30, 31 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a

**THIS PAGE BLANK (USPTO)**

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

substantial portion of a soybean farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 5,7,15 or 17.

4. Claims: 1-22 partly and 27 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a wheat farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 9.

**THIS PAGE BLANK (USPTO)**

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 2

Claims 1 and 2 refer to a polynucleotide or the complement thereof, which encodes a polypeptide with a defined sequence.

Back-translation of the polypeptide generates a very large number of nucleic acid sequences. It is not possible to search for this enormous set of sequences. Therefore, the search has been restricted to the conventional nucleic acid/nucleic acid, protein/protein and protein/six-frame translated nucleic acid comparisons.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C12N 9/10, 15/29, 15/54, 15/70, 15/80		A2	(11) International Publication Number: <b>WO 00/14207</b> (43) International Publication Date: 16 March 2000 (16.03.00)
(21) International Application Number: PCT/US99/20419 (22) International Filing Date: 7 September 1999 (07.09.99) (30) Priority Data: 60/099,521 8 September 1998 (08.09.98) US (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CAHOON, Rebecca, E. [US/US]; 2331 West 18th Street, Wilmington, DE 19806 (US). MIAO, Guo-Hua [CN/US]; 202 Cheery Blossom Place, Hockessin, DE 19707 (US). POWELL, Wayne [GB/US]; 718 Mount Lebanon Road, Wilmington, DE 19803 (US). (74) Agent: MAJARIAN, William, R.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).			(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PLANT FARNESYLTRANSFERASES			
(57) Abstract  This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



TITLE

## PLANT FARNESYLTRANSFERASES

FIELD OF THE INVENTION

5 This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding farnesyltransferase subunits in plants and seeds.

BACKGROUND OF THE INVENTION

10 Lipids and proteins associate covalently to form lipid-linked proteins and noncovalently to form lipoproteins. The lipid portions of lipid-linked proteins anchor their attached proteins to membranes and mediate protein-protein interactions. Proteins form covalent attachments to lipids in several ways, one of which is the covalent attachment of isoprenoid groups, mainly the C<sub>15</sub> farnesyl and C<sub>20</sub> geranylgeranyl residues.

15 In mammals, geranylgeranyltransferase is known to catalyze the transfer of a geranyl-geranyl moiety from geranylgeranyl pyrophosphate to both cysteines in Rab proteins (Farnsworth, C. C. et al. (1994) *Proc Natl Acad Sci U S A* 91(25):11963-11967). Rab proteins are Ras-related small GTPases that are geranylgeranylated on cysteine residues located at or near their C termini. Farnesyltransferase catalyzes the addition of farnesyl groups to the C termini of protein such as Ras.

20 Mammalian protein geranylgeranyl transferases types 1 and 2 are heterodimers composed of an alpha and beta subunit. The alpha subunit shows homology to the alpha subunits of a closely related enzyme, farnesyltransferase. Farnesyltransferases have been described in pea, tomato, and *Arabidopsis*, but have not been described in monocots (Yang et al. (1993) *Plant Physiology* 101:667-674). Plant farnesyltransferases also consist of alpha and beta subunits. The beta subunit is responsible for peptide-binding and contains a catalytic zinc ion. The beta subunit belongs to the protein prenyltransferase beta subunit family. The geranylgeranyl transferase beta subunit also belongs to the protein prenyltransferase beta subunit family. The beta subunits of the type 1 and 2

25 geranylgeranyltransferases have not been previously described in plants. Work done in yeast has established that protein geranylgeranyltransferases are distinct from the closely related protein farnesyltransferases.

30 It has been shown that defects in farnesyltransferase activity enhances plant hormone abscisic acid (ABA) levels. In a normal plant ABA levels increase in response to water deficits. An increase ABA in leaf tissue triggers the closure of leaf stomata to decrease water loss via transpiration (Pei et al. (1998) *Science* 282:287-290). Plants with a decrease in farnesyltransferase activity could confer enhanced tolerance to drought stress in plants. Thus, there is a great deal of interest in identifying the genes that encode farnesyltransferase

in plants. These genes may be used in plant cells to control cell growth and produce plants with improved water stress tolerance. Accordingly, the availability of nucleic acid sequences encoding all or a portion of farnesyltransferase proteins would facilitate studies to better understand cell growth in plants, provide genetic tools to control cell growth and  
5 improve tolerance to drought in mature plants.

#### SUMMARY OF THE INVENTION

The present invention relates to isolated polynucleotides comprising a nucleotide sequence encoding a first polypeptide of at least 300 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected  
10 from the group consisting of a corn farnesyltransferase polypeptide of SEQ ID NO:2, a rice farnesyltransferase polypeptide of SEQ ID NO:4, a soybean farnesyltransferase polypeptide of SEQ ID NO:6, a soybean farnesyltransferase polypeptide of SEQ ID NO:8, a wheat farnesyltransferase polypeptide of SEQ ID NO:10, a corn farnesyltransferase polypeptide of SEQ ID NO:12, a rice farnesyltransferase polypeptide of SEQ ID NO:14, a soybean  
15 farnesyltransferase polypeptide of SEQ ID NO:16, and a soybean farnesyltransferase polypeptide of SEQ ID NO:18. The present invention also relates to an isolated polynucleotide comprising the complement of the nucleotide sequences described above. It is preferred that the isolated polynucleotides of the claimed invention consists of regions of the isolated polynucleotide selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9,  
20 11, 13, 15, and 17 that codes for the polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16 and 18. The present invention also relates to an isolated polynucleotide comprising a nucleotide sequences of at least one of 40 (preferably 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17 and the complement of such nucleotide  
25 sequences.

The present invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to suitable regulatory sequences.

The present invention relates to an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell  
30 may be eucaryotic, such as a yeast or a plant cell, or procaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

The present invention relates to a process for producing an isolated host cell comprising a chimeric gene or isolated polynucleotide of the present invention, the process  
35 comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

The present invention relates to a farnesyltransferase polypeptide of at least 300 amino acids that has at least 80% homology based on the Clustal method of alignment

compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18.

The present invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a farnesyltransferase polypeptide in a plant cell, the method comprising the steps of:

constructing an isolated polynucleotide or chimeric gene of the present invention;

introducing the isolated polynucleotide into a plant cell;

measuring the level of farnesyltransferase polypeptide in the plant cell containing the polynucleotide; and

comparing the level of farnesyltransferase polypeptide in the plant cell containing the isolated polynucleotide with the level of farnesyltransferase polypeptide in a plant cell that does not contain the isolated polynucleotide.

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a farnesyltransferase gene, preferably a plant farnesyltransferase gene, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 40 (preferably 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a farnesyltransferase polypeptide amino acid sequence.

The present invention also relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a farnesyltransferase protein comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

#### BRIEF DESCRIPTION OF THE SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying Sequence Listing which form a part of this application.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1

## Farnesyltransferase Subunits

Protein	Clone Designation	SEQ ID NO: (Nucleotide)	(Amino Acid)
Farnesyltransferase Alpha Subunit	cen3n.pk0052.a2	1	2
Farnesyltransferase Alpha Subunit	rls6.pk0017.g2	3	4
Farnesyltransferase Alpha Subunit	src1c.pk002.f15	5	6
Farnesyltransferase Alpha Subunit	sgs2c.pk006.n4	7	8
Farnesyltransferase Alpha Subunit	Contig composed of: wdk2c.pk013.d24 wrl.pk0110.b1	9	10
Farnesyltransferase Beta Subunit	p0127.cntbu.18r	11	12
Farnesyltransferase Beta Subunit	rlr24.pk0007.d6	13	14
Farnesyltransferase Beta Subunit	sfl1.pk0086.h10	15	16
Farnesyltransferase Beta Subunit	sgs2c.pk002.g2	17	18

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. As used herein, a "polynucleotide" is a nucleotide sequence such as a nucleic acid fragment. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, or synthetic DNA.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping

sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein  
5 changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to  
10 mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional  
15 properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100%  
20 sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more  
25 hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule  
30 would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 40 (preferably 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9,  
35 11, 13, 15, 17 and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a farnesyltransferase polypeptide in a plant cell.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (polynucleotides) encode amino acid sequences that are 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragment encode amino acid sequences that are 85% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are 95% identical to the amino acid sequences reported herein. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively

identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.



The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production

of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

5 "Altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed.

10 "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a  
15 nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*)  
20 may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the  
25 transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

30 Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

35 Nucleic acid fragments encoding at least a portion of several farnesyltransferase subunits have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the

same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g.,  
5 polymerase chain reaction, ligase chain reaction).

For example, genes encoding other farnesyltransferase alpha or beta subunits, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific  
10 oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed  
15 and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in  
20 polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA  
25 precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed  
30 from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a  
35 nucleotide sequence of at least one of 40 (preferably 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17 and the complement of such nucleotide sequences may be used in such

methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a thioredoxin polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of farnesyltransferase activity in those cells.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant*

*Phys. 100:1627-1632*) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds, and is not an inherent part of the invention. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell  
5 extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate  
10 microorganisms via transformation to provide high level expression of the encoded farnesyltransferase subunit. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 7).

All or a substantial portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part  
15 of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then  
20 be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted  
25 and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous  
30 publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used  
35 for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLE 110      Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various corn, rice, soybean and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

## 15      cDNA Libraries from Corn, Rice, Soybean and Wheat

Library	Tissue	Clone
cen3n	Corn endosperm 20 days after pollination*	cen3n.pk0052.a2
	Corn nucellus tissue, 5 days after silking*	p0127.cntbu18r
rlr24	Rice leaf 15 days after germination, 24 hours after infection of strain <i>Magnaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant	rlr24.pk0007.d6
rls6	Rice leaf 15 days after germination, 6 hours after infection of <i>Magnaporthe grisea</i> strain 4360-R-67 (AVR2-YAMO); susceptible	rls6.pk0017.g2
		sfl1.pk0086.h10
sgs2c	Soybean seeds 14 hours after germination	sgs2c.pk006.n4
sgs2c	Soybean seeds 14 hours after germination	sgs2c.pk002.g2
src1c	Soybean 8 day old root infected with cyst nematode <i>Heterodera glycinesis</i>	src1c.pk002.f15
wdk2c	Wheat developing kernel, 7 days after anthesis	wdk2c.pk013.d24
wr1	Wheat root from 7 day old seedling	wr1.pk0110.b1

\*These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be



introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing  
5 recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed  
10 using a Perkin Elmer Model 377 fluorescent sequencer.

## EXAMPLE 2

### Identification of cDNA Clones

cDNA clones encoding farnesyltransferase subunits were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.*  
15 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity  
20 to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For  
25 convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

30

## EXAMPLE 3

### Characterization of cDNA Clones Encoding Farnesyltransferase Alpha Subunits

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to farnesyltransferase alpha subunit from *Pisum sativum* (NCBI Identifier No. gi 2246442) and *Arabidopsis thaliana* (NCBI  
35 Identifier No. gi 3142698). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or contigs assembled from two or more ESTs ("Contig"):

TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous  
to *Pisum sativum* and *Arabidopsis thaliana* Farnesyltransferase Alpha Subunits

Clone	Status	BLAST pLog Score
cen3n.pk0052.a2	FIS	115.00 (gi 2246442)
rls6.pk0017.g2	FIS	121.00 (gi 3142698)
src1c.pk002.f15	FIS	152.00 (gi 2246442)
sgs2c.pk006.n4	FIS	150.00 (gi 2246442)
Contig composed of: wdk2c.pk013.d24 wrl.pk0110.b1	Contig	114.00 (gi 3142698)

5 The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8 and 10 and the *Pisum sativum* and *Arabidopsis thaliana* sequences (SEQ ID NO:19 and 20 respectively). The percent identity between the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8 and 10 ranged between 55-99%.

10

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences  
of cDNA Clones Encoding Polypeptides Homologous  
to *Pisum sativum* and *Arabidopsis thaliana* Farnesyltransferase Alpha Subunits

SEQ ID NO.	Percent Identity to
2	60%
4	62%
6	77%
8	76%
10	62%

15 Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for  
20 pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a farnesyltransferase alpha subunit. These sequences represent the first corn, rice, soybean and wheat sequences encoding a farnesyltransferase  
25 alpha subunit.

EXAMPLE 4Characterization of cDNA Clones Encoding Farnesyltransferase Beta Subunits

The BLASTX search using the EST sequences from clones listed in Table 5 revealed similarity of the polypeptides encoded by the cDNAs to farnesyltransferase beta subunit from *Lycopersicon esculentum* (NCBI Identifier No. gi 1815668), *Pisum sativum* (NCBI Identifier No. gi 417482) and *Pisum sativum* (NCBI Identifier No. gi 169049). Shown in Table 5 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or contigs assembled from two or more ESTs ("Contig"):

TABLE 5

BLAST Results for Sequences Encoding Polypeptides Homologous to *Lycopersicon esculentum* and *Pisum sativum* Farnesyltransferase Beta Subunits

Clone	Status	BLAST pLog Score
p0127.cntbul8r	FIS	149.00 (gi 1815668)
rlr24.pk0007.d6	FIS	110.00 (gi 1815668)
sfl1.pk0086.h10	FIS	>254.00 (gi 417482)
sgs2c.pk002.g2	EST	62.00 (gi 169049)

The data in Table 6 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:12, 14, 16 and 18 and the *Lycopersicon esculentum* (gi 1815668), *Pisum sativum* (gi 417482) and *Pisum sativum* (gi 169049) sequences. The percent identity between the amino acid sequences set forth in SEQ ID NOs:12, 14, 16 and 18 ranged between 50-81%.

TABLE 6

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Lycopersicon esculentum* and *Pisum sativum* Farnesyltransferase Beta Subunits

SEQ ID NO.	Percent Identity to
p0127.cntbul8r	55%
rlr24.pk0007.d6	57%
sfl1.pk0086.h10	77%
sgs2c.pk002.g2	62%

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for

pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a farnesyltransferase beta subunit. These sequences represent the first corn, rice, soybean and wheat sequences encoding a farnesyltransferase beta subunit.

### EXAMPLE 5

#### Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic

proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1  $\mu$ m in diameter) are coated with DNA using the following technique. Ten  $\mu$ g of plasmid DNAs are added to 50  $\mu$ L of a suspension of gold particles (60 mg per mL). Calcium chloride (50  $\mu$ L of a 2.5 M solution) and spermidine free base (20  $\mu$ L of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200  $\mu$ L of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30  $\mu$ L of ethanol. An aliquot (5  $\mu$ L) of the DNA-coated gold particles can be placed in the center of a Kapton<sup>TM</sup> flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic<sup>TM</sup> PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-

supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 6

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), SmaI, KpnI and XbaI. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent

No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

5 A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al.(1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then  
10 be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µl spermidine (0.1 M), and 50 µL CaCl<sub>2</sub> (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70%  
15 ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette.  
20 For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

25 Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into  
30 individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 7

##### Expression of Chimeric Genes in Microbial Cells

35 The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter

system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.



CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence encoding a first polypeptide of at least 300 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a corn farnesyltransferase polypeptide of SEQ ID NO:2, a rice farnesyltransferase polypeptide of SEQ ID NO:4, a soybean farnesyltransferase polypeptide of SEQ ID NO:6, a soybean farnesyltransferase polypeptide of SEQ ID NO:8, a wheat farnesyltransferase polypeptide of SEQ ID NO:10, a corn farnesyltransferase polypeptide of SEQ ID NO:12, a rice farnesyltransferase polypeptide of SEQ ID NO:14, a soybean farnesyltransferase polypeptide of SEQ ID NO:16, and a soybean farnesyltransferase polypeptide of SEQ ID NO:18.
2. An isolated polynucleotide comprising the complement of the polynucleotide of Claim 1.
3. The isolated polynucleotide of Claim 1, wherein the nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15 and 17 that codes for the polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16 and 18.
4. The isolated polynucleotide of Claim 1 which is DNA.
5. The isolated polynucleotide of Claim 1 which is RNA.
6. A chimeric gene comprising the isolated polynucleotide of Claim 1 or Claim 2 operably linked to suitable regulatory sequences.
7. An isolated host cell comprising the chimeric gene of Claim 6.
8. An isolated host cell comprising an isolated polynucleotide of Claim 1.
9. The isolated host cell of Claim 8, wherein the host cell is yeast.
10. The isolated host cell of Claim 8, wherein the host cell is a bacterial cell.
11. The isolated host cell of Claim 8, wherein the host cell is a plant cell.
12. A virus comprising the isolated polynucleotide of Claim 1.
13. A process for producing an isolated host cell comprising the chimeric gene of Claim 6, the process comprising either transforming or transfecting an isolated compatible host cell with the chimeric gene of Claim 6.
14. A farnesyltransferase polypeptide of at least 300 amino acids that has at least 80% homology based on the Clustal method of alignment compared to a polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16 and 18.
15. A method of selecting an isolated polynucleotide that affects the level of expression of a farnesyltransferase polypeptide in a plant cell, the method comprising the steps of:

constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17 and the complement of such nucleotide sequences;

5                   introducing the isolated polynucleotide into a plant cell;

                  measuring the level of farnesyltransferase polypeptide in the plant cell containing the polynucleotide; and

                  comparing the level of farnesyltransferase polypeptide in the plant cell containing the isolated polynucleotide with the level of farnesyltransferase polypeptide in a  
10   plant cell that does not contain the polynucleotide.

16. The method of Claim 15 wherein the isolated polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, and 17 that codes for the polypeptide selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16 and 18.

15           17. The method of Claim 15 wherein the isolated polynucleotide is DNA.

18. The method of Claim 15 wherein the isolated polynucleotide is RNA.

19. The method of Claim 15 wherein the isolated polynucleotide is a chimeric gene comprising the nucleotide sequence operably linked to suitable regulatory sequences.

20           20. A method of selecting an isolated polynucleotide that affects the level of expression of farnesyltransferase polypeptide in a plant cell, the method comprising the steps of:

                  constructing the isolated polynucleotide of Claim 1;

                  introducing the isolated polynucleotide into a plant cell;

25           21.           measuring the level of farnesyltransferase polypeptide in the plant cell containing the polynucleotide; and

                  comparing the level of farnesyltransferase polypeptide in the plant cell containing the isolated polynucleotide with the level of farnesyltransferase polypeptide in a plant cell that does not contain the isolated polynucleotide.

30           22. A method of obtaining a nucleic acid fragment encoding a substantial portion of a farnesyltransferase gene comprising the steps of:

                  synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 40 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17 and the complement of such nucleotide sequences; and

35           23.           amplifying a nucleic acid sequence using the oligonucleotide primer.

22. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a farnesyltransferase protein comprising the steps of:

probing a cDNA or genomic library with an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, and the complement of such nucleotide sequences;

- 5 identifying a DNA clone that hybridizes with the isolated polynucleotide;  
isolating the identified DNA clone; and  
sequencing the cDNA or genomic fragment that comprises the isolated DNA  
clone.

23. The isolated polynucleotide of Claim 1, wherein the first polypeptide is  
10 compared to the corn farnesyltransferase polypeptide of SEQ ID NO:2.

24. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the rice farnesyltransferase polypeptide of SEQ ID NO:4.

25. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the soybean farnesyltransferase polypeptide of SEQ ID NO:6.

15 26. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the soybean farnesyltransferase polypeptide of SEQ ID NO:8.

27. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the wheat farnesyltransferase polypeptide of SEQ ID NO:10.

28. The isolated polynucleotide of Claim 1, wherein the first polypeptide is  
20 compared to the corn farnesyltransferase polypeptide of SEQ ID NO:12.

29. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the rice farnesyltransferase polypeptide of SEQ ID NO:14.

30. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the soybean farnesyltransferase polypeptide of SEQ ID NO:16.

25 31. The isolated polynucleotide of Claim 1, wherein the first polypeptide is compared to the soybean farnesyltransferase polypeptide of SEQ ID NO:18.

**THIS PAGE BLANK (USPTO)**

23-1240  
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C12N 9/10, 15/29, 15/54, 15/70, 15/80		A3	(11) International Publication Number: WO 00/14207
			(43) International Publication Date: 16 March 2000 (16.03.00)
(21) International Application Number: PCT/US99/20419		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 7 September 1999 (07.09.99)		Published With international search report.	
(30) Priority Data: 60/099,521 8 September 1998 (08.09.98) US		(88) Date of publication of the international search report: 17 August 2000 (17.08.00)	
(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).		<b>RECEIVED</b>  SEP 07 2000  PATENT RECORDS CENTER	
(72) Inventors; and (75) Inventors/Applicants (for US only): CAHOON, Rebecca, E. [US/US]; 2331 West 18th Street, Wilmington, DE 19806 (US). MIAO, Guo-Hua [CN/US]; 202 Cheery Blossum Place, Hockessin, DE 19707 (US). POWELL, Wayne [GB/US]; 718 Mount Lebanon Road, Wilmington, DE 19803 (US).			
(74) Agent: MAJARIAN, William, R.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).			
(54) Title: PLANT FARNESYLTRANSFERASES			
(57) Abstract  This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
HJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 99/20419

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/10 C12N15/29 C12N15/54 C12N15/70 C12N15/80

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	QIAN ET AL: "Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control" PLANT CELL, vol. 8, 1996, page 2381-2394 XP002090873 ROCKVILLE US ISSN: 1040-4651 page 2390 -page 2392	1,2,4, 6-8,10, 11,13,14
A	---	22, 24-26,29
	-/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 April 2000

Date of mailing of the international search report

15. 5. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

# INTERNATIONAL SEARCH REPORT

Int. lional Application No

PCT/US 99/20419

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YANG Z ET AL: "PROTEIN FARNESYLTRANSFERASE IN PLANTS 1 MOLECULAR CLONING AND EXPRESSION OF A HOMOLOG OF THE BETA SUBUNIT FROM THE GARDEN PEA" PLANT PHYSIOLOGY, vol. 101, no. 2, 1993, page 667-674 XP000647522 ROCKVILLE US ISSN: 0032-0889 cited in the application abstract; figure 2</p>	1-5, 22, 30
A	---	22, 31
A	<p>CUTLER S. ET AL: "A protein farnesyl-transferase involved in abscisic acid signal transduction in arabidopsis" SCIENCE, vol. 273, August 1996 (1996-08), page 1239-1241 XP002090871 WASHINGTON US ISSN: 0036-8075</p>	1
A	<p>YALOVSKY S. ET AL.: "Plant farnesyl transferase can restore yeast ras signaling and mating" MOLECULAR AND CELLULAR BIOLOGY., vol. 17, no. 4, 1997, pages 1986-1994, XP000864327 WASHINGTON., US ISSN: 0270-7306 abstract</p>	1-5, 22, 27, 29
A	<p>HATA S. ET AL.: "cDNA cloning of squalene synthase genes from mono- and dicotyledonous plants, and expression of the gene in rice." PLANT AND CELL PHYSIOLOGY, vol. 38, no. 12, 1997, pages 1409-1413, XP000864329 abstract</p>	1
A	<p>MERLOT ET AL: "Genetic analysis of abscisic acid signal transduction" PLANT PHYSIOLOGY, vol. 114, 1997, page 751-757 XP002090872 ROCKVILLE US the whole document</p>	1
A	<p>SKOCZYLAS E. ET AL.: "Protein farnesyltransferase in plants" BIOCHIMIE, vol. 78, no. 2, 1996, pages 139-143, XP000864561 page 141, paragraph 2; figure 2</p>	1-5, 14, 22, 27



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/20419

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 2  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 2

Claims 1 and 2 refer to a polynucleotide or the complement thereof, which encodes a polypeptide with a defined sequence.

Back-translation of the polypeptide generates a very large number of nucleic acid sequences. It is not possible to search for this enormous set of sequences. Therefore, the search has been restricted to the conventional nucleic acid/nucleic acid, protein/protein and protein/six-frame translated nucleic acid comparisons.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-22 partly and 23, 28 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a corn farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 1 or SEQ.ID.NO: 11.

2. Claims: 1-22 partly and 24, 29 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a rice farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 3 or SEQ.ID.NO: 13.

3. Claims: 1-22 partly and 25, 26, 30, 31 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

substantial portion of a soybean farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 5,7,15 or 17.

4. Claims: 1-22 partly and 27 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a wheat farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 9.

SEQUENCE LISTING

<110> Cahoon, Rebecca E.  
Miao, Gou-Hau  
Powell, Wayne

<120> Plant Farnesyltransferases

<130> BB-1240

<140>

<141>

<150> 60/099,521

<151> September 8, 1998

<160> 23

<170> Microsoft Office 97

<210> 1

<211> 1426

<212> DNA

<213> Zea mays

<400> 1

```

gcacgagaca gcgcaattac ttaagctatt tgtattcgga tctgatccaa ccctgggtggt 60
cagctggact catcgcccat ggagcacact aagtcaggcc ccagcagttg gccagaactg 120
gccgacgtgg tgccgggtgcc gcaggacgat gggcctagcc ctgtgggtgtc catcgccctat 180
cgagatgact ttctgtgaggt catggattac ttccgcgccc tctacctcac cgggtgagcga 240
agccctcgcg ctctccgcct caccgcccag gccatcgagc tcaaccccgg caactacact 300
gtctggcatt tccggcgccct tattctggag tcaactagatt ttgatttact agaggagatg 360
aaattttgtcg aaaaaattgc tgaatgcaat ccaaaaaatt accaaatctg gcaccataag 420
agatggccttg ctgagaaaatt aggacctggg attgcaaaca aagagcatga attcacaatg 480
aagatacttg ctattgatgc aaaaaattat catgcttggt ctcataggca gtgggttctt 540
caagcgttgg ggggatggga gactgaatta gaatactgtg accacttact taaggaagac 600
gtcttcaata attcagcttg gaatcagaga tactttgtta taacaagatc accatttctt 660
gggtggccttg cggcaatgcg tgattcagaa gtagactaca caattgaagc tattctagca 720
aacgctcaga atgaaagccc ctggagggtac ctcaagggtc tatacaaggg tgagaataac 780
ctgctagtag aggacgagcg catctctgct gtttgtttca aggtcctgaa gaatgattgg 840
acttgtgtat ttgctttgag tttgctgtct gatcttctct gcactgggtt gcagccttca 900
gatgaactta ggtccactct tgaaacaata aggagctccc atcctgaaac cgcggatgat 960
gatectgcag ccgctgtttg ctgtatcctg cagaaatgtg atcccctgcg ggtaaattat 1020
tggtcttggg tcaaggacac tctttctcag atctcatgac ttcacatggg ttcacccctt 1080
gtccgcgctg gtccgggctc tgtgagatag acatgtttta gatagtttca ttggacaccc 1140
aaaacagagcg gacagagtgt atggctgcta ccttctccgt gactgaaagc agtgcttgta 1200
acgattttgt ttagtaaaaat ttgtgagtgt tactgtcca aacaacacct tatgcaacca 1260
tatttgaata tttcacatgt aagcttgaat ccagggtgtgt ttgttaatgt attacaattg 1320
ccatgggagc ctaaatgaga ccataatca cttccactag agtcggaaga ccgtgtcgag 1380
cagttcactc atatggtcac ttaaagcaaa aaaaaaaaaa aaaaaa 1426

```

<210> 2

<211> 326

<212> PRT

<213> Zea mays

<400> 2

Met Glu His Thr Lys Ser Gly Pro Ser Ser Trp Pro Glu Leu Ala Asp

1

5

10

15

**THIS PAGE BLANK (USPTO)**

Val	Val	Pro	Val	Pro	Gln	Asp	Asp	Gly	Pro	Ser	Pro	Val	Val	Ser	Ile	20	25	30
Ala	Tyr	Arg	Asp	Asp	Phe	Arg	Glu	Val	Met	Asp	Tyr	Phe	Arg	Ala	Leu	35	40	45
Tyr	Leu	Thr	Gly	Glu	Arg	Ser	Pro	Arg	Ala	Leu	Arg	Leu	Thr	Ala	Glu	50	55	60
Ala	Ile	Glu	Leu	Asn	Pro	Gly	Asn	Tyr	Thr	Val	Trp	His	Phe	Arg	Arg	65	70	75 80
Leu	Ile	Leu	Glu	Ser	Leu	Asp	Phe	Asp	Leu	Leu	Glu	Glu	Met	Lys	Phe	85	90	95
Val	Glu	Lys	Ile	Ala	Glu	Cys	Asn	Pro	Lys	Asn	Tyr	Gln	Ile	Trp	His	100	105	110
His	Lys	Arg	Trp	Leu	Ala	Glu	Lys	Leu	Gly	Pro	Gly	Ile	Ala	Asn	Lys	115	120	125
Glu	His	Glu	Phe	Thr	Met	Lys	Ile	Leu	Ala	Ile	Asp	Ala	Lys	Asn	Tyr	130	135	140
His	Ala	Trp	Ser	His	Arg	Gln	Trp	Val	Leu	Gln	Ala	Leu	Gly	Gly	Trp	145	150	155 160
Glu	Thr	Glu	Leu	Glu	Tyr	Cys	Asp	His	Leu	Leu	Lys	Glu	Asp	Val	Phe	165	170	175
Asn	Asn	Ser	Ala	Trp	Asn	Gln	Arg	Tyr	Phe	Val	Ile	Thr	Arg	Ser	Pro	180	185	190
Phe	Leu	Gly	Gly	Leu	Ala	Ala	Met	Arg	Asp	Ser	Glu	Val	Asp	Tyr	Thr	195	200	205
Ile	Glu	Ala	Ile	Leu	Ala	Asn	Ala	Gln	Asn	Glu	Ser	Pro	Trp	Arg	Tyr	210	215	220
Leu	Lys	Gly	Leu	Tyr	Lys	Gly	Glu	Asn	Asn	Leu	Leu	Val	Glu	Asp	Glu	225	230	235 240
Arg	Ile	Ser	Ala	Val	Cys	Phe	Lys	Val	Leu	Lys	Asn	Asp	Trp	Thr	Cys	245	250	255
Val	Phe	Ala	Leu	Ser	Leu	Leu	Leu	Asp	Leu	Leu	Cys	Thr	Gly	Leu	Gln	260	265	270
Pro	Ser	Asp	Glu	Leu	Arg	Ser	Thr	Leu	Glu	Thr	Ile	Arg	Ser	Ser	His	275	280	285
Pro	Glu	Thr	Ala	Asp	Asp	Asp	Pro	Ala	Ala	Ala	Val	Cys	Cys	Ile	Leu	290	295	300
Gln	Lys	Cys	Asp	Pro	Leu	Arg	Val	Asn	Tyr	Trp	Ser	Trp	Phe	Lys	Asp	305	310	315 320
Thr	Leu	Ser	Gln	Ile	Ser											325		

**THIS PAGE BLANK (USPTO)**



<210> 3  
 <211> 1218  
 <212> DNA  
 <213> Oryza sativa

<400> 3  
 gcacgaggtt ctaacgccgc cgccgccgcc gccgtctccg cagaatctga tcgatggcgc 60  
 cgctcgtegac gtcgtcggag ggtgcctccg acgagtgggt gccacccagc cggcgggccgg 120  
 agctggcgga cgtggtcccc gtgacgcagg acgacggggc ccaccccggt gtggccatcg 180  
 cctaccggga cgagtccgc gaggtcatgg actacttccg cgccctctac ttcgccggcg 240  
 agcgcagcgt ccgcgccctc cacctcaccg ccgaggtcat cgaccttaat cccggcaact 300  
 acacggtgtg gcattttagg cgtcttggtc tagaggcact ggatgctgat ctgcgtgagg 360  
 aaatggattt tgtggaccga attgctgaat gtaacccaaa aaattatcaa atctggcatc 420  
 acaagagatg gcttgccggag aaattaggac cagatattgc aaataaagag cacgaattta 480  
 caaggaagat actttctatg gatgctaaaa attaccatgc ttggtctcat aggcagtggg 540  
 ttcttcaagc actgggtgga tgggagactg aactacagta ttgcaaccag ctgcttgagg 600  
 aagacgtctt caataattca gcttggaatc agagatacct tgtaataaca agttcaccac 660  
 ttcttgaggg ccttgcagca atgcgtgact cggaagtggg ttacacagtt ggggctattc 720  
 tggctaacc tcaaatgaa agccctgga gatacctcaa aggcctgtac aagggtgaaa 780  
 ataacttgct gatggctgat gagcgcatct ctgatgtttg tctcaaggtc ctgaaacatg 840  
 attcgacctg cgtatttgct ttgagcttgc tgctcgatct tcttcaaatt ggtttacaac 900  
 cttcagatga actcaaagga actatcgaa caataaagaa ctctgatcct gaagcagatg 960  
 aagcagtaga tgctgatctt gcgactgcaa tctgctcaat attgcagaga tgtgatcccc 1020  
 tgcggataaa ttactgggcc tggtagagga ccactatttc ttctcaaacc tgaagcatgc 1080  
 agtggcctcc atgaggtcat aatggagata tcttctatct tegtgtgatt ctgggcgttg 1140  
 aggtgcctag ctacatttgt tatgaacttt ccttgggcat aactgatcac tgatattact 1200  
 ccaatattgt gttctaaa 1218

<210> 4  
 <211> 339  
 <212> PRT  
 <213> Oryza sativa

<400> 4  
 Met Ala Pro Ser Ser Thr Ser Ser Glu Gly Ala Ser Asp Glu Trp Leu  
 1 5 10 15  
 Pro Pro Ser Arg Arg Pro Glu Leu Ala Asp Val Val Pro Val Thr Gln  
 20 25 30  
 Asp Asp Gly Pro His Pro Val Val Ala Ile Ala Tyr Arg Asp Glu Phe  
 35 40 45  
 Arg Glu Val Met Asp Tyr Phe Arg Ala Leu Tyr Phe Ala Gly Glu Arg  
 50 55 60  
 Ser Val Arg Ala Leu His Leu Thr Ala Glu Val Ile Asp Leu Asn Pro  
 65 70 75 80  
 Gly Asn Tyr Thr Val Trp His Phe Arg Arg Leu Val Leu Glu Ala Leu  
 85 90 95  
 Asp Ala Asp Leu Arg Glu Glu Met Asp Phe Val Asp Arg Ile Ala Glu  
 100 105 110  
 Cys Asn Pro Lys Asn Tyr Gln Ile Trp His His Lys Arg Trp Leu Ala  
 115 120 125  
 Glu Lys Leu Gly Pro Asp Ile Ala Asn Lys Glu His Glu Phe Thr Arg  
 130 135 140

**THIS PAGE BLANK (USPTO)**

Lys Ile Leu Ser Met Asp Ala Lys Asn Tyr His Ala Trp Ser His Arg  
 145 150 155 160  
 Gln Trp Val Leu Gln Ala Leu Gly Gly Trp Glu Thr Glu Leu Gln Tyr  
 165 170 175  
 Cys Asn Gln Leu Leu Glu Glu Asp Val Phe Asn Asn Ser Ala Trp Asn  
 180 185 190  
 Gln Arg Tyr Leu Val Ile Thr Ser Ser Pro Leu Leu Gly Gly Leu Ala  
 195 200 205  
 Ala Met Arg Asp Ser Glu Val Asp Tyr Thr Val Gly Ala Ile Leu Ala  
 210 215 220  
 Asn Pro Gln Asn Glu Ser Pro Trp Arg Tyr Leu Lys Gly Leu Tyr Lys  
 225 230 235 240  
 Gly Glu Asn Asn Leu Leu Met Ala Asp Glu Arg Ile Ser Asp Val Cys  
 245 250 255  
 Leu Lys Val Leu Lys His Asp Ser Thr Cys Val Phe Ala Leu Ser Leu  
 260 265 270  
 Leu Leu Asp Leu Leu Gln Ile Gly Leu Gln Pro Ser Asp Glu Leu Lys  
 275 280 285  
 Gly Thr Ile Glu Ala Ile Lys Asn Ser Asp Pro Glu Ala Asp Glu Ala  
 290 295 300  
 Val Asp Ala Asp Leu Ala Thr Ala Ile Cys Ser Ile Leu Gln Arg Cys  
 305 310 315 320  
 Asp Pro Leu Arg Ile Asn Tyr Trp Ser Trp Tyr Arg Thr Thr Ile Ser  
 325 330 335

Ser Gln Thr

<210> 5  
 <211> 1261  
 <212> DNA  
 <213> Glycine max

<400> 5  
 gcacgaggat taacgaagga tggaaatctgg gtctagcgaa ggagaagagg tgcagcaacg 60  
 cgtgccggttg agggagagag tggagtggtc agatgttact ccggttcctc aaaacgacgg 120  
 ccctaaccct gtcgttcgga tccagtacac tgaagagttt tccgaagtta tggattactt 180  
 tcgcgccggtt tacctcaccg atgaacgctc cctcgcgcc ctcgctctca cagccgaagc 240  
 cgttcaattc aactccggca actacactgt gtggcatttc cgacggttgt tacttgagtc 300  
 gctaaaagtc gacttgaacg atgaactgga ttttgtggag cgtatggccg ctggaaattc 360  
 taaaaattat cagatgtggc atcatagacg atgggttgcc gagaagttag gtcctgaagc 420  
 tagaaacaat gagctcgagt tcaccaaata gatactgtcc gttgatgcca aacattatca 480  
 tgcattgtct catagacagt gggctcttca aacactagga ggatgggaag atgaacttaa 540  
 ttattgcaca gaactactta aagaagacat ttttaacaat tctgcttgga atcagagata 600  
 ttttgtcata acaaggtctc ctttcttggg gggcctaaaa gctatgagag agtctgaagt 660  
 gctttacacc attgaagcca ttatagccta cctgaaaaat gaaagctcgt ggagatatct 720  
 acgaggactt tataaagggtg aaactacttc atgggtaaat gatcctcaag tttcttcagt 780  
 atgcttaag attttgagaa ctaagagcaa ctacgtgttt gctcttagca ctattttaga 840

**THIS PAGE BLANK (USPTO)**

```

tcttatatgc tttggttate aaccaaataga agacattaga gatgccattg acgccttaaa 900
gaccgcagat atggataaac aagatttaga tgatgatgag aaaggggaac aacaaaattt 960
aaatatagca cgaaatattt gttctatcct aaaacaagtt gatccaatta gaaccaacta 1020
ttggatttgg cgcaagagca gacttcctct atcagcttag taaccaaagt aattaaagg 1080
caactctgtg ttatgtgtaa cctagtttat tgaaactgga tttttattta ttattatttt 1140
ttatgttgc atgtatctgt ttgtgcaaat ttatcttttt gtcatgccat tactggcatt 1200
tgagtgtgtaag gattgaaagc catgcagaat aagaaattta agtttttttt tccgttgaaa 1260
a 1261

```

<210> 6  
 <211> 346  
 <212> PRT  
 <213> Glycine max

<400> 6  
 Met Glu Ser Gly Ser Ser Glu Gly Glu Glu Val Gln Gln Arg Val Pro  
 1 5 10 15  
 Leu Arg Glu Arg Val Glu Trp Ser Asp Val Thr Pro Val Pro Gln Asn  
 20 25 30  
 Asp Gly Pro Asn Pro Val Val Pro Ile Gln Tyr Thr Glu Glu Phe Ser  
 35 40 45  
 Glu Val Met Asp Tyr Phe Arg Ala Val Tyr Leu Thr Asp Glu Arg Ser  
 50 55 60  
 Pro Arg Ala Leu Ala Leu Thr Ala Glu Ala Val Gln Phe Asn Ser Gly  
 65 70 75 80  
 Asn Tyr Thr Val Trp His Phe Arg Arg Leu Leu Leu Glu Ser Leu Lys  
 85 90 95  
 Val Asp Leu Asn Asp Glu Leu Asp Phe Val Glu Arg Met Ala Ala Gly  
 100 105 110  
 Asn Ser Lys Asn Tyr Gln Met Trp His His Arg Arg Trp Val Ala Glu  
 115 120 125  
 Lys Leu Gly Pro Glu Ala Arg Asn Asn Glu Leu Glu Phe Thr Lys Lys  
 130 135 140  
 Ile Leu Ser Val Asp Ala Lys His Tyr His Ala Trp Ser His Arg Gln  
 145 150 155 160  
 Trp Ala Leu Gln Thr Leu Gly Gly Trp Glu Asp Glu Leu Asn Tyr Cys  
 165 170 175  
 Thr Glu Leu Leu Lys Glu Asp Ile Phe Asn Asn Ser Ala Trp Asn Gln  
 180 185 190  
 Arg Tyr Phe Val Ile Thr Arg Ser Pro Phe Leu Gly Gly Leu Lys Ala  
 195 200 205  
 Met Arg Glu Ser Glu Val Leu Tyr Thr Ile Glu Ala Ile Ile Ala Tyr  
 210 215 220  
 Pro Glu Asn Glu Ser Ser Trp Arg Tyr Leu Arg Gly Leu Tyr Lys Gly  
 225 230 235 240

**THIS PAGE BLANK (USPTO)**

Glu Thr Thr Ser Trp Val Asn Asp Pro Gln Val Ser Ser Val Cys Leu  
245 250 255

Lys Ile Leu Arg Thr Lys Ser Asn Tyr Val Phe Ala Leu Ser Thr Ile  
260 265 270

Leu Asp Leu Ile Cys Phe Gly Tyr Gln Pro Asn Glu Asp Ile Arg Asp  
275 280 285

Ala Ile Asp Ala Leu Lys Thr Ala Asp Met Asp Lys Gln Asp Leu Asp  
290 295 300

Asp Asp Glu Lys Gly Glu Gln Gln Asn Leu Asn Ile Ala Arg Asn Ile  
305 310 315 320

Cys Ser Ile Leu Lys Gln Val Asp Pro Ile Arg Thr Asn Tyr Trp Ile  
325 330 335

Trp Arg Lys Ser Arg Leu Pro Leu Ser Ala  
340 345

<210> 7  
<211> 1333  
<212> DNA  
<213> Glycine max

<400> 7  
gcacgagctt gcgtgtggag tgaagaagat taacgaagga tggaatctgg gtctagcgaa 60  
ggagaagagg tgcagcaacg cgtgccgttg agggagagag tggagtggtc agatgttact 120  
ccggttcctc aaaacgacgg ccctaaccct gtcgttccga tccagtacac tgaagagttt 180  
tccgaagtta tggattactt tcgcgccgtt tacctcaccg atgaacgctc cctcgcgcc 240  
ctcgctctca cagccgaagc cgttcaattc aactcoggca actacactgt gtggcatttc 300  
cgacggttgt tacttgagtc gctaaaagtc gacttgaacg atgaactgga gtttgtggag 360  
cgtatggccg ctggaaattc taaaaattat cagatgtggg gtgatgctct gctctgctct 420  
ttcttcata ctttgcata tagacgatgg gttgcccaga agttaggctc tgaagctaga 480  
aacaatgagc tcgagttcac caaaaagata ctgtccgttg atgccaaaca ttatcatgca 540  
tggtctcata gacagtgggc tcttcaaaca ctaggaggat gggaagatga acttaattat 600  
tgcacagaac tacttaaaga agacattttt aacaattctg cttggaatca gagatatttt 660  
gtcataacaa ggtctccttt cttggggggc ctaaaagcta tgagagagtc tgaagtgttt 720  
tacaccattg aagccattat agcctaccct gaaaatgaaa gctcgtggag atatctacga 780  
ggactttata aaggtgaaac tacttcatgg gtaaatgata ctcaagtttc ttcagtatgc 840  
ttaaagattt tgagaactaa gagcaactac gtgtttgtct ttagcactat tttagatctt 900  
atatgctttg gttatcaacc aatgaagac attagagatg ccattgacgc cttaaagacc 960  
gcagatatgg ataaacaaga tttagatgat gatgagaaag gggaacaaca aaatttaaat 1020  
atagcacgaa atatttggtc taccctaaaa caagttgatc caattagaac caactattgg 1080  
atttggcgca agagcagact tcctctatca gcttagtaac caaagtaatt aaagggcaac 1140  
tctgtgttat gtgtaacctt gtttattgaa actggatgtt tatttattat tattttttat 1200  
gttgtcatgt atctgtttgt gcaaatttat ctttttgtca tgccattact ggcatttgag 1260  
tgtaaggatt gaaagccatg cagaataaga aatttaagtt tttttttccg ttgaaaaaaa 1320  
aaaaaaaaaa aaa 1333

<210> 8  
<211> 358  
<212> PRT  
<213> Glycine max

<400> 8  
Met Glu Ser Gly Ser Ser Glu Gly Glu Glu Val Gln Gln Arg Val Pro  
1 5 10 15

**THIS PAGE BLANK (USPTO)**



Leu Arg Glu Arg Val	Glu Trp Ser Asp Val	Thr Pro Val Pro Gln Asn
20	25	30
Asp Gly Pro Asn Pro	Val Val Pro Ile Gln Tyr	Thr Glu Glu Phe Ser
35	40	45
Glu Val Met Asp Tyr	Phe Arg Ala Val Tyr	Leu Thr Asp Glu Arg Ser
50	55	60
Pro Arg Ala Leu Ala	Leu Thr Ala Glu Ala	Val Gln Phe Asn Ser Gly
65	70	75 80
Asn Tyr Thr Val Trp	His Phe Arg Arg Leu	Leu Leu Glu Ser Leu Lys
85	90	95
Val Asp Leu Asn Asp	Glu Leu Glu Phe Val	Glu Arg Met Ala Ala Gly
100	105	110
Asn Ser Lys Asn Tyr	Gln Met Trp Cys Asp	Ala Leu Leu Cys Ser Phe
115	120	125
Phe His Thr Leu His	His Arg Arg Trp Val	Ala Glu Lys Leu Gly Pro
130	135	140
Glu Ala Arg Asn Asn	Glu Leu Glu Phe Thr	Lys Lys Ile Leu Ser Val
145	150	155 160
Asp Ala Lys His Tyr	His Ala Trp Ser His	Arg Gln Trp Ala Leu Gln
165	170	175
Thr Leu Gly Gly Trp	Glu Asp Glu Leu Asn	Tyr Cys Thr Glu Leu Leu
180	185	190
Lys Glu Asp Ile Phe	Asn Asn Ser Ala Trp	Asn Gln Arg Tyr Phe Val
195	200	205
Ile Thr Arg Ser Pro	Phe Leu Gly Gly Leu	Lys Ala Met Arg Glu Ser
210	215	220
Glu Val Leu Tyr Thr	Ile Glu Ala Ile Ile	Ala Tyr Pro Glu Asn Glu
225	230	235 240
Ser Ser Trp Arg Tyr	Leu Arg Gly Leu Tyr	Lys Gly Glu Thr Thr Ser
245	250	255
Trp Val Asn Asp Pro	Gln Val Ser Ser Val	Cys Leu Lys Ile Leu Arg
260	265	270
Thr Lys Ser Asn Tyr	Val Phe Ala Leu Ser	Thr Ile Leu Asp Leu Ile
275	280	285
Cys Phe Gly Tyr Gln	Pro Asn Glu Asp Ile	Arg Asp Ala Ile Asp Ala
290	295	300
Leu Lys Thr Ala Asp	Met Asp Lys Gln Asp	Leu Asp Asp Asp Glu Lys
305	310	315 320
Gly Glu Gln Gln Asn	Leu Asn Ile Ala Arg	Asn Ile Cys Ser Ile Leu
325	330	335

**THIS PAGE BLANK (USPTO)**

Lys Gln Val Asp Pro Ile Arg Thr Asn Tyr Trp Ile Trp Arg Lys Ser  
 340 345 350

Arg Leu Pro Leu Ser Ala  
 355

<210> 9  
 <211> 1339  
 <212> DNA  
 <213> Triticum aestivum

<400> 9  
 cggacgtggc gccgctgccg caggccgacg ggccttgcgc cgtcgtctcc atcgtttacc 60  
 gcggcgactt ccgcgaggtc atggactact tccgcgcctt ctacgccgcc ggcgagcgca 120  
 gccccgcgc cctccgcctc accgcgacg ccatccacct caaccccgcc aactacactg 180  
 tatggcattt caggcgcggtt gttctagagg cactggatgc tgatttattg ctagaaatgc 240  
 attttgtgga ccaaattgct gaatctaata caaaaaatta ccaagtctgg catcacaaga 300  
 gatggcttgc tgagaaaata ggaccagatg ctgcaaatag tgaacatgac ttcacaagga 360  
 agatacttgc tatggatgct aaaaactacc atgcttggtc ccataggcag tgggttcttc 420  
 aagcattggg tggatgggag agtgaactgc agtactgcaa ccagcttctt gaggaagatg 480  
 tcttcaataa ctcagcttgg aatcagagat accttgtggt aacacgatca ccaattcttg 540  
 ggggccttgc ggcaatgcgc gactcagaag tagattacac agttgaggcc attatggtga 600  
 accctcagaa tgaaagcccc tggagatacc tcagagggtt atataaggat gataacaatt 660  
 tgctggtggc tgataatcgc atttctgatg cttgcctcaa ggtcctgaat aaggattgga 720  
 catgcgtatt tgctttgagc ttctgtcttg atcttcttcg catgggttgc cagccttcga 780  
 atgaacttaa aggaaccatc gaagcaatgg agaactctga tcttgaaacg ggacatgctg 840  
 atattgcagt agctgtctgc tcaatcctgc agaaatgtga tcccctgcgg ataaactact 900  
 ggtcatggta ccagaccact ctttcttctt agacatctga aaattcagct gaagacagtt 960  
 ttagcagcat gatgtaaact caatcgaagg ggttgacgca gtgtatgaaa aacctttcct 1020  
 gtgatcttgg tgcggagcaa tttgtactga ttttactggg aaaaatcaat caatgacagc 1080  
 atgccaaca atgtcttgtg tgaatatgtt actgcctgat attcacatgt tagcagaatg 1140  
 agaataacca atcaaaactcc aacgagcaga ttgttacagt aacggccact ggtggtgtga 1200  
 aaatcctgaa atctgcttca gtcactttgc cttgtttaca gttgagctcg ttgttgtgat 1260  
 ctgtacctaa tgcatgtaca caatcatcaa attattagtt tttgtaccaa tgagtattcg 1320  
 atgaaaaaaaa aaaaaaaaaa 1339

<210> 10  
 <211> 309  
 <212> PRT  
 <213> Triticum aestivum

<400> 10  
 Asp Val Ala Pro Leu Pro Gln Ala Asp Gly Pro Cys Pro Val Val Ser  
 1 5 10 15  
 Ile Ala Tyr Arg Gly Asp Phe Arg Glu Val Met Asp Tyr Phe Arg Ala  
 20 25 30  
 Leu Tyr Ala Ala Gly Glu Arg Ser Pro Arg Ala Leu Arg Leu Thr Ala  
 35 40 45  
 Asp Ala Ile His Leu Asn Pro Gly Asn Tyr Thr Val Trp His Phe Arg  
 50 55 60  
 Arg Val Val Leu Glu Ala Leu Asp Ala Asp Leu Leu Leu Glu Met His  
 65 70 75 80  
 Phe Val Asp Gln Ile Ala Glu Ser Asn Pro Lys Asn Tyr Gln Val Trp  
 85 90 95

**THIS PAGE BLANK (USPTO)**

His His Lys Arg Trp Leu Ala Glu Lys Ile Gly Pro Asp Ala Ala Asn  
 100 105 110  
 Ser Glu His Asp Phe Thr Arg Lys Ile Leu Ala Met Asp Ala Lys Asn  
 115 120 125  
 Tyr His Ala Trp Ser His Arg Gln Trp Val Leu Gln Ala Leu Gly Gly  
 130 135 140  
 Trp Glu Ser Glu Leu Gln Tyr Cys Asn Gln Leu Leu Glu Glu Asp Val  
 145 150 155 160  
 Phe Asn Asn Ser Ala Trp Asn Gln Arg Tyr Leu Val Val Thr Arg Ser  
 165 170 175  
 Pro Ile Leu Gly Gly Leu Ala Ala Met Arg Asp Ser Glu Val Asp Tyr  
 180 185 190  
 Thr Val Glu Ala Ile Met Val Asn Pro Gln Asn Glu Ser Pro Trp Arg  
 195 200 205  
 Tyr Leu Arg Gly Leu Tyr Lys Asp Asp Asn Asn Leu Leu Val Ala Asp  
 210 215 220  
 Asn Arg Ile Ser Asp Ala Cys Leu Lys Val Leu Asn Lys Asp Trp Thr  
 225 230 235 240  
 Cys Val Phe Ala Leu Ser Phe Leu Leu Asp Leu Leu Arg Met Gly Leu  
 245 250 255  
 Gln Pro Ser Asn Glu Leu Lys Gly Thr Ile Glu Ala Met Glu Asn Ser  
 260 265 270  
 Asp Pro Glu Thr Gly His Ala Asp Ile Ala Val Ala Val Cys Ser Ile  
 275 280 285  
 Leu Gln Lys Cys Asp Pro Leu Arg Ile Asn Tyr Trp Ser Trp Tyr Gln  
 290 295 300  
 Thr Thr Leu Ser Ser  
 305

<210> 11  
 <211> 1359  
 <212> DNA  
 <213> Zea mays

<400> 11  
 atggacccct ccccgagtc gacgcccgcc accggagacg acccggcagc ggcggcggat 60  
 cccgacctac cgaggctcac ggtgacgcag gtggagcaga tgaagggtga ggccagggtt 120  
 ggcgacatct accgctccct cttcgggggc gcgccaaca cgaaatccat catgctagag 180  
 ctgtggcggtg atcagcatat cgagtatctg acgcctgggc tgaggcatat gggaccagcc 240  
 tttcatgttc tagatgcaa tcgccttggt ctatgctact ggatgggttca tccacttgct 300  
 ttgctggatg aagcacttga tgatgatctt gagaatgata tcatagactt cttagctcga 360  
 tgtcaggata aagatggtgg atatagtggg ggacctggac agttgcctca cctagctacg 420  
 acttatgctg ctgtaaatac acttggtgaca atagggagcg aaagagcatt gtcataatc 480  
 aataggggca acctgtacaa ttttatgctg cagatgaaag atgtatcagg tgctttcaga 540  
 atgcatgatg gtggcgaaat tgatgtccgt gcttcctaca ccgctatatc gggttgccagc 600  
 cttgtgaata ttcttgattt taaactggca aaaggtgtag gcgactacat agcaagatgt 660  
 caaacttatg aaggtggtat tgctggggag ccttatgctg aagcacatgg tgggtatata 720

**THIS PAGE BLANK (USPTO)**

```

ttctgtggat tggctgcttt gatcctgctt aatgaggcag agaaagttga cttgcctagt 780
ttgattggct gggtggtctt tcgtcaagga gtggaatgcg gatttcaagg acgaactaat 840
aaattgggtg atgggttgcta ctcttttgg cagggagctg ccattgcttt cacacaaaag 900
ttaattacga ttgttgataa gcaattgaag tcctcgatatt cctgcaaaaag gccatcagga 960
gaggatgcct gcagcaccag ttcatatggg tgcaccgcga aaaagtcttc ctctgctgtg 1020
gactatgcga agtttggatt tgattttata caacagagca accaaattgg cccactcttc 1080
cataacattg ccctgcaaca atacatccta ctttgttctc aggtactaga gggaggcttg 1140
agggataagc ctggaaagaa cagagatcac tatcattcat gctactgcct cagtggcctc 1200
gcagttagcc agtacagtgc catgactgat actgggtcgt gccattacc tcagcatgtg 1260
cttggaccgt actctaattt gctggagcca atccatccac tctacaatgt tgtcctagat 1320
aagtaccata cagcctatga gttcttctca gaagagtga 1359

```

<210> 12  
 <211> 452  
 <212> PRT  
 <213> Zea mays

<400> 12

Met Asp Pro Ser Pro Gln Ser Thr Pro Pro Thr Gly Asp Asp Pro Ala  
 1 5 10 15

Ala Ala Ala Asp Pro Asp Leu Pro Arg Leu Thr Val Thr Gln Val Glu  
 20 25 30

Gln Met Lys Val Glu Ala Arg Val Gly Asp Ile Tyr Arg Ser Leu Phe  
 35 40 45

Gly Ala Ala Pro Asn Thr Lys Ser Ile Met Leu Glu Leu Trp Arg Asp  
 50 55 60

Gln His Ile Glu Tyr Leu Thr Pro Gly Leu Arg His Met Gly Pro Ala  
 65 70 75 80

Phe His Val Leu Asp Ala Asn Arg Pro Trp Leu Cys Tyr Trp Met Val  
 85 90 95

His Pro Leu Ala Leu Leu Asp Glu Ala Leu Asp Asp Asp Leu Glu Asn  
 100 105 110

Asp Ile Ile Asp Phe Leu Ala Arg Cys Gln Asp Lys Asp Gly Gly Tyr  
 115 120 125

Ser Gly Gly Pro Gly Gln Leu Pro His Leu Ala Thr Thr Tyr Ala Ala  
 130 135 140

Val Asn Thr Leu Val Thr Ile Gly Ser Glu Arg Ala Leu Ser Ser Ile  
 145 150 155 160

Asn Arg Gly Asn Leu Tyr Asn Phe Met Leu Gln Met Lys Asp Val Ser  
 165 170 175

Gly Ala Phe Arg Met His Asp Gly Gly Glu Ile Asp Val Arg Ala Ser  
 180 185 190

Tyr Thr Ala Ile Ser Val Ala Ser Leu Val Asn Ile Leu Asp Phe Lys  
 195 200 205

Leu Ala Lys Gly Val Gly Asp Tyr Ile Ala Arg Cys Gln Thr Tyr Glu  
 210 215 220

**THIS PAGE BLANK (USPTO)**



Gly Gly Ile Ala Gly Glu Pro Tyr Ala Glu Ala His Gly Gly Tyr Thr  
 225 230 235 240  
 Phe Cys Gly Leu Ala Ala Leu Ile Leu Leu Asn Glu Ala Glu Lys Val  
 245 250 255  
 Asp Leu Pro Ser Leu Ile Gly Trp Val Ala Phe Arg Gln Gly Val Glu  
 260 265 270  
 Cys Gly Phe Gln Gly Arg Thr Asn Lys Leu Val Asp Gly Cys Tyr Ser  
 275 280 285  
 Phe Trp Gln Gly Ala Ala Ile Ala Phe Thr Gln Lys Leu Ile Thr Ile  
 290 295 300  
 Val Asp Lys Gln Leu Lys Ser Ser Tyr Ser Cys Lys Arg Pro Ser Gly  
 305 310 315 320  
 Glu Asp Ala Cys Ser Thr Ser Ser Tyr Gly Cys Thr Ala Lys Lys Ser  
 325 330 335  
 Ser Ser Ala Val Asp Tyr Ala Lys Phe Gly Phe Asp Phe Ile Gln Gln  
 340 345 350  
 Ser Asn Gln Ile Gly Pro Leu Phe His Asn Ile Ala Leu Gln Gln Tyr  
 355 360 365  
 Ile Leu Leu Cys Ser Gln Val Leu Glu Gly Gly Leu Arg Asp Lys Pro  
 370 375 380  
 Gly Lys Asn Arg Asp His Tyr His Ser Cys Tyr Cys Leu Ser Gly Leu  
 385 390 395 400  
 Ala Val Ser Gln Tyr Ser Ala Met Thr Asp Thr Gly Ser Cys Pro Leu  
 405 410 415  
 Pro Gln His Val Leu Gly Pro Tyr Ser Asn Leu Leu Glu Pro Ile His  
 420 425 430  
 Pro Leu Tyr Asn Val Val Leu Asp Lys Tyr His Thr Ala Tyr Glu Phe  
 435 440 445  
 Phe Ser Glu Glu  
 450

<210> 13  
 <211> 1031  
 <212> DNA  
 <213> *Oryza sativa*

<400> 13  
 gcacgagggc gtagccgcct ttcggtgaga tccccgcggc tgcagcgagc tgcagggccg 60  
 ccgccttccg cgccgcgcac caccgcgccc atggaccccc cctcgccgcc gccgcgcgcg 120  
 ccatatcctc ctgctgctgc tgagggcggt ccggcagcgg atagccaggc cgctgagctg 180  
 ccccggtgta ctgtgacgca ggtggagcag atgaaggtgg aggcgaaggt gggcgaaatc 240  
 taccgcgtcc tcttcggcaa cgcgcccaac gccaatcccc tcatgttaga gctgtggcgt 300  
 gagcagcatg ttgagtattt gacgagaggg ctgaaacatc ttggaccaag cttccatgtg 360  
 ctcgatgcc aatcgacctg gctgtgctac tggattattc atgcacttgc tctgttgatg 420  
 gaaataacctg acgatgttga ggatgatatt gtggacttct tatctcgatg tcaggacaaa 480  
 gatgggtggtt atggcgaggg acctggacag ttgcctcatc tcgctacaac ttatgctgct 540

**THIS PAGE BLANK (USPTO)**

```

gtaaatacac ttgtaactat agggagtgaag agggcactat catcggtaaa cagggaacaac 600
ctgtacaagt tcatgcttcg gatgaaagat acatcgggag ctttcagaat gcatgatggt 660
ggtgaaatag atgttcgtgc tagctatact gcaatatcgg ttgccagcct tgtgaacatt 720
cttgatggtg aactagcaaa aggtgttgga aattacataa caaggtgtca aacctatgaa 780
ggtggcattg ctggggaacc gtatgctgaa gctcatgggtg ggtacacttt ttgtgggctg 840
gctacgatga tcctgcttaa cgaagtggac aaacttgatt tggctagctt gattggctgg 900
gtggcatttc gccaaaggag ggaatgtgga tttcaaggac gaactaataa attggttgat 960
ggttgctact ccttttgga gggagctgct cttgctttaa ctgttcaccg cgtggcgccg 1020
actgccaaac g 1031

```

<210> 14  
 <211> 313  
 <212> PRT  
 <213> *Oryza sativa*

<400> 14  
 Met Asp Pro Pro Ser Pro Pro Pro Pro Pro Tyr Pro Pro Ala Ala  
 1 5 10 15  
 Ala Glu Gly Gly Pro Ala Ala Asp Ser Gln Ala Ala Glu Leu Pro Arg  
 20 25 30  
 Leu Thr Val Thr Gln Val Glu Gln Met Lys Val Glu Ala Lys Val Gly  
 35 40 45  
 Glu Ile Tyr Arg Val Leu Phe Gly Asn Ala Pro Asn Ala Asn Ser Leu  
 50 55 60  
 Met Leu Glu Leu Trp Arg Glu Gln His Val Glu Tyr Leu Thr Arg Gly  
 65 70 75 80  
 Leu Lys His Leu Gly Pro Ser Phe His Val Leu Asp Ala Asn Arg Pro  
 85 90 95  
 Trp Leu Cys Tyr Trp Ile Ile His Ala Leu Ala Leu Leu Asp Glu Ile  
 100 105 110  
 Pro Asp Asp Val Glu Asp Asp Ile Val Asp Phe Leu Ser Arg Cys Gln  
 115 120 125  
 Asp Lys Asp Gly Gly Tyr Gly Gly Gly Pro Gly Gln Leu Pro His Leu  
 130 135 140  
 Ala Thr Thr Tyr Ala Ala Val Asn Thr Leu Val Thr Ile Gly Ser Glu  
 145 150 155 160  
 Arg Ala Leu Ser Ser Val Asn Arg Asp Asn Leu Tyr Lys Phe Met Leu  
 165 170 175  
 Arg Met Lys Asp Thr Ser Gly Ala Phe Arg Met His Asp Gly Gly Glu  
 180 185 190  
 Ile Asp Val Arg Ala Ser Tyr Thr Ala Ile Ser Val Ala Ser Leu Val  
 195 200 205  
 Asn Ile Leu Asp Gly Glu Leu Ala Lys Gly Val Gly Asn Tyr Ile Thr  
 210 215 220  
 Arg Cys Gln Thr Tyr Glu Gly Gly Ile Ala Gly Glu Pro Tyr Ala Glu  
 225 230 235 240

**THIS PAGE BLANK (USPTO)**

Ala His Gly Gly Tyr Thr Phe Cys Gly Leu Ala Thr Met Ile Leu Leu  
245 250 255

Asn Glu Val Asp Lys Leu Asp Leu Ala Ser Leu Ile Gly Trp Val Ala  
260 265 270

Phe Arg Gln Gly Val Glu Cys Gly Phe Gln Gly Arg Thr Asn Lys Leu  
275 280 285

Val Asp Gly Cys Tyr Ser Phe Trp Gln Gly Ala Ala Leu Ala Leu Thr  
290 295 300

Val His Arg Val Ala Pro Thr Ala Lys  
305 310

<210> 15

<211> 1504

<212> DNA

<213> Glycine max

<400> 15

```
gcacgaggac aaatccgccg ccgccgccgc cgtgtccgac ggtgagtcaa cgtgagcaat 60
ggatggtaga gtgcgagggtg tticagattt accaactctt cgccaccatt cctcgcaacg 120
cccaaaccct catgttggag cttcaacgcg ataatcacat gcagtatgtc tccaaaggcc 180
ttcgccatct cagttccgca ttttcggtt tggacgctaa tcgaccctgg ctctgctact 240
ggatcttcca ctccattgct ttgtcgggag aatccgtcga tgatgaactc gaagataacg 300
ctatcgattt tcttaaccgt tgccaggatc cgaatggtgg atatgccggg ggaccaggcc 360
agatgcctca tattgccaca acttatgctg ctgttaattc acttattact ttgggtggtg 420
agaaatccct ggcatacaat aatagagata aactgtatgg gtttctgcgg cggatgaagc 480
aaccaaatgg tggattcagg atgcatgatg aagggtgaaat tgatgttcga gcttgctaca 540
ctgccatttc tgttgcaagt gttttgaaca ttttgatga tgagctgatc cagaatggtg 600
gagactacat tataagctgt caaacatatg aggggtggcat tgctggtgag cctgggttctg 660
aggctcatgg tgggtacacc ttttgtggat tagctacaat gattctgatt ggtgagggtta 720
atcacttggg tctgcctcga ttagttgact ggggtggtatt ccgacaagggt aaggaaatgtg 780
gattccaggg gagaacaaat aaactgggtg atggatgcta ttccttttgg caggggagggtg 840
ctgttgctct attgcaaaga ttatcttcta ttatcaacaa acagatggaa gagacatcac 900
agatttttgc ggtatcttat gtatctgaag caaaagaaag tttggatgga acctctagtc 960
atgcaacatg ccgtggtgag catgaaggca ccagtgaatc cagttcatct gatttttaaaa 1020
atattgccta taaatttatt aatgagtggg gagcacaaga accacttttt cacagtattg 1080
ctttacagca atatattctc ttatgtgcac aggagcaaga ggggtggactg agagacaaac 1140
cgggtaaacg tagagatcat tatcacacat gttactgttt aagtggactc tcattgtgcc 1200
agtatagttg gtcaaagcac ccagattctc caccactgcc taatctagta ttaggccctc 1260
actctaactc cttagaacca atccaccccc tctttaatgt tgtcttggga cgatatcgtg 1320
aagctcatga attcttcttt actgagtcgt gaccactggg tttagctacc aacaacttta 1380
tttgataaat gtaaaataaa ttcattggaa catataaatg taaaacagca ttggattaaa 1440
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaa 1504
```

<210> 16

<211> 429

<212> PRT

<213> Glycine max

<400> 16

Met Val Glu Ser Gln Val Phe Gln Ile Tyr Gln Leu Phe Ala Thr Ile  
1 5 10 15

Pro Arg Asn Ala Gln Thr Leu Met Leu Glu Leu Gln Arg Asp Asn His  
20 25 30

**THIS PAGE BLANK (USPTO)**

Met	Gln	Tyr	Val	Ser	Lys	Gly	Leu	Arg	His	Leu	Ser	Ser	Ala	Phe	Ser	35	40	45	
Val	Leu	Asp	Ala	Asn	Arg	Pro	Trp	Leu	Cys	Tyr	Trp	Ile	Phe	His	Ser	50	55	60	
Ile	Ala	Leu	Ser	Gly	Glu	Ser	Val	Asp	Asp	Glu	Leu	Glu	Asp	Asn	Ala	65	70	75	80
Ile	Asp	Phe	Leu	Asn	Arg	Cys	Gln	Asp	Pro	Asn	Gly	Gly	Tyr	Ala	Gly	85	90	95	
Gly	Pro	Gly	Gln	Met	Pro	His	Ile	Ala	Thr	Thr	Tyr	Ala	Ala	Val	Asn	100	105	110	
Ser	Leu	Ile	Thr	Leu	Gly	Gly	Glu	Lys	Ser	Leu	Ala	Ser	Ile	Asn	Arg	115	120	125	
Asp	Lys	Leu	Tyr	Gly	Phe	Leu	Arg	Arg	Met	Lys	Gln	Pro	Asn	Gly	Gly	130	135	140	
Phe	Arg	Met	His	Asp	Glu	Gly	Glu	Ile	Asp	Val	Arg	Ala	Cys	Tyr	Thr	145	150	155	160
Ala	Ile	Ser	Val	Ala	Ser	Val	Leu	Asn	Ile	Leu	Asp	Asp	Glu	Leu	Ile	165	170	175	
Gln	Asn	Val	Gly	Asp	Tyr	Ile	Ile	Ser	Cys	Gln	Thr	Tyr	Glu	Gly	Gly	180	185	190	
Ile	Ala	Gly	Glu	Pro	Gly	Ser	Glu	Ala	His	Gly	Gly	Tyr	Thr	Phe	Cys	195	200	205	
Gly	Leu	Ala	Thr	Met	Ile	Leu	Ile	Gly	Glu	Val	Asn	His	Leu	Asp	Leu	210	215	220	
Pro	Arg	Leu	Val	Asp	Trp	Val	Val	Phe	Arg	Gln	Gly	Lys	Glu	Cys	Gly	225	230	235	240
Phe	Gln	Gly	Arg	Thr	Asn	Lys	Leu	Val	Asp	Gly	Cys	Tyr	Ser	Phe	Trp	245	250	255	
Gln	Gly	Gly	Ala	Val	Ala	Leu	Leu	Gln	Arg	Leu	Ser	Ser	Ile	Ile	Asn	260	265	270	
Lys	Gln	Met	Glu	Glu	Thr	Ser	Gln	Ile	Phe	Ala	Val	Ser	Tyr	Val	Ser	275	280	285	
Glu	Ala	Lys	Glu	Ser	Leu	Asp	Gly	Thr	Ser	Ser	His	Ala	Thr	Cys	Arg	290	295	300	
Gly	Glu	His	Glu	Gly	Thr	Ser	Glu	Ser	Ser	Ser	Ser	Asp	Phe	Lys	Asn	305	310	315	320
Ile	Ala	Tyr	Lys	Phe	Ile	Asn	Glu	Trp	Arg	Ala	Gln	Glu	Pro	Leu	Phe	325	330	335	
His	Ser	Ile	Ala	Leu	Gln	Gln	Tyr	Ile	Leu	Leu	Cys	Ala	Gln	Glu	Gln	340	345	350	

**THIS PAGE BLANK (USPTO)**



Glu Gly Gly Leu Arg Asp Lys Pro Gly Lys Arg Arg Asp His Tyr His  
355 360 365

Thr Cys Tyr Cys Leu Ser Gly Leu Ser Leu Cys Gln Tyr Ser Trp Ser  
370 375 380

Lys His Pro Asp Ser Pro Pro Leu Pro Asn Leu Val Leu Gly Pro Tyr  
385 390 395 400

Ser Asn Leu Leu Glu Pro Ile His Pro Leu Phe Asn Val Val Leu Gly  
405 410 415

Arg Tyr Arg Glu Ala His Glu Phe Phe Phe Thr Glu Ser  
420 425

<210> 17  
<211> 533  
<212> DNA  
<213> Glycine max

<220>  
<221> unsure  
<222> (499)

<220>  
<221> unsure  
<222> (525)

<400> 17  
gagagagata cgaatccggc ggccggcgcca ccgtgtccga cgggtgagtca acgggaccag 60  
tggatggttag agtcgcaggt gtttcagatt taccaactct ttgccaccat tcctggcagc 120  
gcccaaaacc tcatgttaga gctgcaacgc gataatcaca tgcagtatct ctccaaaggc 180  
ctacgccatc tcagttccgc gttttctgtc ttggaacgta atcgaccctg gctctgttac 240  
tggatcttcc attccattgc tttgctggga gaatccgtcg acgacgaact cgaagataac 300  
actatcgatt ttcttaaccg ttgccaggat ccgaatggtg gatatgctgg gggaccaggc 360  
cagatgcctc acattgccac aacatatgct gcagttaata cacttattac tttgggtggt 420  
cagaaatcct ggcatacaatt aataggtgag ataaactgta tgggtttctg cggcgggatga 480  
agcaatcaaa tggggggant caagatgcat gatgaaagga gaaanttgat gtc 533

<210> 18  
<211> 141  
<212> PRT  
<213> Glycine max

<400> 18  
Asp Thr Asn Pro Ala Ala Ala Pro Pro Cys Pro Thr Val Ser Gln Arg  
1 5 10 15

Asp Gln Trp Met Val Glu Ser Gln Val Phe Gln Ile Tyr Gln Leu Phe  
20 25 30

Ala Thr Ile Pro Gly Ser Ala Gln Asn Leu Met Leu Glu Leu Gln Arg  
35 40 45

Asp Asn His Met Gln Tyr Leu Ser Lys Gly Leu Arg His Leu Ser Ser  
50 55 60

Ala Phe Ser Val Leu Asp Ala Asn Arg Pro Trp Leu Cys Tyr Trp Ile  
65 70 75 80

**THIS PAGE BLANK (USPTO)**

Phe His Ser Ile Ala Leu Leu Gly Glu Ser Val Asp Asp Glu Leu Glu  
85 90 95

Asp Asn Thr Ile Asp Phe Leu Asn Arg Cys Gln Asp Pro Asn Gly Gly  
100 105 110

Tyr Ala Gly Gly Pro Gly Gln Met Pro His Ile Ala Thr Thr Tyr Ala  
115 120 125

Ala Val Asn Thr Leu Ile Thr Leu Gly Gly Gln Lys Ser  
130 135 140

<210> 19

<211> 333

<212> PRT

<213> Pisum sativum

<400> 19

Met Ala Gly Asn Ile Glu Val Glu Glu Asp Asp Arg Val Pro Leu Arg  
1 5 10 15

Leu Arg Pro Glu Trp Ser Asp Val Thr Pro Ile Pro Gln Asp Asp Gly  
20 25 30

Pro Ser Pro Val Val Pro Ile Asn Tyr Ser Glu Glu Phe Ser Glu Val  
35 40 45

Met Asp Tyr Phe Arg Ala Val Tyr Phe Ala Lys Glu Leu Ser Ser Arg  
50 55 60

Ala Leu Ala Leu Thr Ala Glu Ala Ile Gly Leu Asn Ala Gly Asn Tyr  
65 70 75 80

Thr Val Trp His Phe Arg Arg Leu Leu Leu Glu Ser Leu Lys Val Asp  
85 90 95

Leu His Val Glu Arg Glu Phe Val Glu Arg Val Ala Ser Gly Asn Ser  
100 105 110

Lys Asn Tyr Gln Ile Trp His His Arg Arg Trp Val Ala Glu Lys Leu  
115 120 125

Gly Pro Glu Ala Arg Asn Ser Glu Leu Glu Phe Thr Lys Lys Ile Leu  
130 135 140

Ser Val Asp Ala Lys His Tyr His Ala Trp Ser His Arg Gln Trp Val  
145 150 155 160

Leu Gln Asn Leu Gly Gly Trp Glu Asp Glu Leu Ser Tyr Cys Ser Glu  
165 170 175

Leu Leu Ala Glu Asp Ile Phe Asn Asn Ser Ala Trp Asn Gln Arg Tyr  
180 185 190

Phe Val Ile Thr Arg Ser Pro Val Leu Gly Gly Leu Lys Ala Met Arg  
195 200 205

Glu Ser Glu Val Leu Phe Thr Val Glu Ala Ile Ile Ser Tyr Pro Glu  
210 215 220

**THIS PAGE BLANK (USPTO)**

Asn Glu Ser Ser Trp Arg Tyr Leu Arg Gly Leu Phe Lys Asp Glu Ser  
 225 230 235 240  
 Thr Leu Tyr Val Asn Asp Ala Gln Val Ser Ser Leu Cys Leu Lys Ile  
 245 250 255  
 Leu Lys Thr Lys Ser Asn Tyr Leu Phe Ala Leu Ser Thr Leu Leu Asp  
 260 265 270  
 Leu Ser Ala Ser Val Ile Gln Pro Asn Glu Asp Phe Arg Asp Ala Ile  
 275 280 285  
 Glu Ala Leu Arg Leu Gln Ile Leu Ile Lys Gln Asp Ser Asp Ile Ala  
 290 295 300  
 Ile Thr Ile Cys Ser Ile Leu Glu Gln Val Asp Pro Ile Arg Val Asn  
 305 310 315 320  
 Tyr Trp Val Trp Arg Lys Ser Arg Leu Pro Gln Ala Ala  
 325 330

<210> 20  
 <211> 326  
 <212> PRT  
 <213> Arabidopsis thaliana

<400> 20  
 Met Asn Phe Asp Glu Thr Val Pro Leu Ser Gln Arg Leu Glu Trp Ser  
 1 5 10 15  
 Asp Val Val Pro Leu Thr Gln Asp Asp Gly Pro Asn Pro Val Val Pro  
 20 25 30  
 Ile Ala Tyr Lys Glu Glu Phe Arg Glu Thr Met Asp Tyr Phe Arg Ala  
 35 40 45  
 Ile Tyr Phe Ser Asp Glu Arg Ser Pro Arg Ala Leu Arg Leu Thr Glu  
 50 55 60  
 Glu Thr Leu Leu Leu Asn Ser Gly Asn Tyr Thr Val Trp His Phe Arg  
 65 70 75 80  
 Arg Leu Val Leu Glu Ala Leu Asn His Asp Leu Phe Glu Glu Leu Glu  
 85 90 95  
 Phe Ile Glu Arg Ile Ala Glu Asp Asn Ser Lys Asn Tyr Gln Leu Trp  
 100 105 110  
 His His Arg Arg Trp Val Ala Glu Lys Leu Gly Pro Asp Val Ala Gly  
 115 120 125  
 Arg Glu Leu Glu Phe Thr Arg Arg Val Leu Ser Leu Asp Ala Lys His  
 130 135 140  
 Tyr His Ala Trp Ser His Arg Gln Trp Thr Leu Arg Ala Leu Gly Gly  
 145 150 155 160  
 Trp Glu Asp Glu Leu Asp Tyr Cys His Glu Leu Leu Glu Ala Asp Val  
 165 170 175

**THIS PAGE BLANK (USPTO)**

Phe Asn Asn Ser Ala Trp Asn Gln Arg Tyr Tyr Val Ile Thr Gln Ser  
 180 185 190  
 Pro Leu Leu Gly Gly Leu Glu Ala Met Arg Glu Ser Glu Val Ser Tyr  
 195 200 205  
 Thr Ile Lys Ala Ile Leu Thr Asn Pro Ala Asn Glu Ser Ser Trp Arg  
 210 215 220  
 Tyr Leu Lys Ala Leu Tyr Lys Asp Asp Lys Glu Ser Trp Ile Ser Asp  
 225 230 235 240  
 Pro Ser Val Ser Ser Val Cys Leu Asn Val Leu Ser Arg Thr Asp Cys  
 245 250 255  
 Phe His Gly Phe Ala Leu Ser Thr Leu Leu Asp Leu Leu Cys Asp Gly  
 260 265 270  
 Leu Arg Pro Thr Asn Glu His Lys Asp Ser Val Arg Ala Leu Ala Asn  
 275 280 285  
 Glu Glu Pro Glu Thr Asn Leu Ala Asn Leu Val Cys Thr Ile Leu Gly  
 290 295 300  
 Arg Val Asp Pro Ile Arg Ala Asn Tyr Trp Ala Trp Arg Lys Ser Lys  
 305 310 315 320  
 Ile Thr Val Ala Ala Ile  
 325

<210> 21  
 <211> 470  
 <212> PRT  
 <213> Lycopersicon esculentum

<400> 21  
 Met Glu Ser Arg Lys Val Thr Lys Thr Leu Glu Asp Gln Trp Val Val  
 1 5 10 15  
 Glu Arg Arg Val Arg Glu Ile Tyr Asp Tyr Phe Tyr Ser Ile Ser Pro  
 20 25 30  
 Asn Ser Pro Ser Asp Leu Ile Glu Ile Glu Arg Asp Lys His Phe Gly  
 35 40 45  
 Tyr Leu Ser Gln Gly Leu Arg Lys Leu Gly Pro Ser Phe Ser Val Leu  
 50 55 60  
 Asp Ala Ser Arg Pro Trp Leu Cys Tyr Trp Thr Leu His Ser Ile Ala  
 65 70 75 80  
 Leu Leu Gly Glu Ser Ile Gly Gly Lys Leu Glu Asn Asp Ala Ile Asp  
 85 90 95  
 Phe Leu Thr Arg Cys Gln Asp Lys Asp Gly Gly Tyr Gly Gly Gly Pro  
 100 105 110  
 Gly Gln Met Pro His Leu Ala Thr Thr Tyr Ala Ala Val Asn Ser Leu  
 115 120 125

**THIS PAGE BLANK (USPTO)**



Ile Thr Leu Gly Lys	Pro Glu Ala Leu Ser	Ser Ile Asn Arg Glu Lys
130	135	140
Leu Tyr Thr Phe Leu	Leu Arg Met Lys Asp	Ala Ser Gly Gly Phe Arg
145	150	155 160
Met His Asp Gly Gly	Glu Val Asp Val Arg	Ala Cys Tyr Thr Ala Ile
165	170	175
Ser Val Ala Asn Ile	Leu Asn Ile Val Asp	Asp Glu Leu Ile His Gly
180	185	190
Val Gly Asn Tyr Ile	Leu Ser Cys Gln Thr	Tyr Glu Gly Gly Ile Ala
195	200	205
Gly Glu Pro Gly Ser	Glu Ala His Gly Gly	Tyr Thr Phe Cys Gly Leu
210	215	220
Ala Ala Met Ile Leu	Ile Asn Glu Val Asp	Arg Leu Asp Leu Pro Gly
225	230	235 240
Leu Ile Asp Trp Val	Val Phe Arg Gln Gly	Val Glu Gly Gly Phe Gln
245	250	255
Gly Arg Thr Asn Lys	Leu Val Asp Gly Cys	Tyr Ser Phe Trp Gln Gly
260	265	270
Ala Val Val Phe Leu	Ile Gln Arg Leu Asn	Leu Ile Val His Glu Gln
275	280	285
Leu Gly Leu Ser Asn	Asp Leu Ser Thr Glu	Ser Ala Asp Asp Ser Ser
290	295	300
Glu Ser Glu Leu Ser	Asp Glu Glu Glu His	Leu Glu Gly Ile Ser Ser
305	310	315 320
His Val Gln Asp Thr	Phe Pro Leu Gly Gln	Ala Gly Ala Cys Gln Glu
325	330	335
Asn Ala Ser His Ser	Pro Lys Ile Ala Asp	Thr Gly Tyr Glu Phe Ile
340	345	350
Asn Arg Pro Ile Ala	Met Arg Pro Leu Phe	Asp Ser Met Tyr Leu Gln
355	360	365
Gln Tyr Val Leu Leu	Cys Ser Gln Ile Glu	Val Gly Gly Phe Arg Asp
370	375	380
Lys Pro Gly Lys Gly	Arg Asp Tyr Tyr His	Thr Cys Tyr Cys Leu Ser
385	390	395 400
Gly Leu Ser Ile Ala	Gln Tyr Ser Trp Thr	Asp Glu Ala Asp Ser Thr
405	410	415
Pro Leu Pro Arg Asp	Val Phe Gly Pro Tyr	Ser Lys Cys Leu Leu Glu
420	425	430
Gln Val His Pro Leu	Phe Asn Val Val Leu	Asp Arg Tyr Tyr Glu Ala
435	440	445

**THIS PAGE BLANK (USPTO)**

Arg Glu Tyr Ser Gln Ala Cys Glu Thr Val Ser Pro Leu Ser Leu Ala  
 450 455 460

Pro Thr Phe Ser Glu Thr  
 465 470

<210> 22  
 <211> 419  
 <212> PRT  
 <213> Pisum sativum

<400> 22  
 Met Glu Ala Ser Thr Ala Ala Glu Thr Pro Thr Pro Thr Val Ser Gln  
 1 5 10 15

Arg Asp Gln Trp Ile Val Glu Ser Gln Val Phe His Ile Tyr Gln Leu  
 20 25 30

Phe Ala Asn Ile Pro Pro Asn Ala Gln Ser Ile Ile Arg Pro Trp Leu  
 35 40 45

Cys Tyr Trp Ile Ile His Ser Ile Ala Leu Leu Gly Glu Ser Ile Asp  
 50 55 60

Asp Asp Leu Glu Asp Asn Thr Val Asp Phe Leu Asn Arg Cys Gln Asp  
 65 70 75 80

Pro Asn Gly Gly Tyr Ala Gly Gly Pro Gly Gln Met Pro His Leu Ala  
 85 90 95

Thr Thr Tyr Ala Ala Val Asn Thr Leu Ile Thr Leu Gly Gly Glu Lys  
 100 105 110

Ser Leu Ala Ser Ile Asn Arg Asn Lys Leu Tyr Gly Phe Met Arg Arg  
 115 120 125

Met Lys Gln Pro Asn Gly Gly Phe Arg Met His Asp Glu Gly Glu Ile  
 130 135 140

Asp Val Arg Ala Cys Tyr Thr Ala Ile Ser Val Ala Ser Val Leu Asn  
 145 150 155 160

Ile Leu Asp Asp Glu Leu Ile Lys Asn Val Gly Asp Phe Ile Leu Ser  
 165 170 175

Cys Gln Thr Tyr Glu Gly Gly Leu Ala Gly Glu Pro Gly Ser Glu Ala  
 180 185 190

His Gly Gly Tyr Thr Phe Cys Gly Leu Ala Ala Met Ile Leu Ile Gly  
 195 200 205

Glu Val Asn Arg Leu Asp Leu Pro Arg Leu Leu Asp Trp Val Val Phe  
 210 215 220

Arg Gln Gly Lys Glu Cys Gly Phe Gln Gly Arg Thr Asn Lys Leu Val  
 225 230 235 240

Asp Gly Cys Tyr Ser Phe Trp Gln Gly Gly Ala Val Ala Leu Leu Gln  
 245 250 255

**THIS PAGE BLANK (USPTO)**

Arg Leu His Ser Ile Ile Asp Glu Gln Met Ala Glu Ala Ser Gln Phe  
 260 265 270  
 Val Thr Val Ser Asp Ala Pro Glu Glu Lys Glu Cys Leu Asp Gly Thr  
 275 280 285  
 Ser Ser His Ala Thr Ser His Ile Arg His Glu Gly Met Asn Glu Ser  
 290 295 300  
 Cys Ser Ser Asp Val Lys Asn Ile Gly Tyr Asn Phe Ile Ser Glu Trp  
 305 310 315 320  
 Arg Gln Ser Glu Pro Leu Phe His Ser Ile Ala Leu Gln Gln Tyr Ile  
 325 330 335  
 Leu Leu Cys Ser Gln Glu Gln Asp Gly Gly Leu Arg Asp Lys Pro Gly  
 340 345 350  
 Lys Arg Arg Asp His Tyr His Ser Cys Tyr Cys Leu Ser Gly Leu Ser  
 355 360 365  
 Leu Cys Gln Tyr Ser Trp Ser Lys Arg Pro Asp Ser Pro Pro Leu Pro  
 370 375 380  
 Lys Val Val Met Gly Pro Tyr Ser Asn Leu Leu Glu Pro Ile His Pro  
 385 390 395 400  
 Leu Phe Asn Val Val Leu Asp Arg Tyr Arg Glu Ala His Glu Phe Phe  
 405 410 415  
 Ser Gln Leu

<210> 23  
 <211> 419  
 <212> PRT  
 <213> Pisum sativum

<400> 23  
 Met Glu Ala Ser Thr Ala Ala Glu Thr Pro Thr Pro Thr Val Ser Gln  
 1 5 10 15  
 Arg Asp Gln Trp Ile Val Glu Ser Gln Val Phe His Ile Tyr Gln Leu  
 20 25 30  
 Phe Ala Asn Ile Pro Pro Asn Ala Gln Ser Ile Ile Arg Pro Trp Leu  
 35 40 45  
 Cys Tyr Trp Ile Ile His Ser Ile Ala Leu Leu Gly Glu Ser Ile Asp  
 50 55 60  
 Asp Asp Leu Glu Asp Asn Thr Val Asp Phe Leu Asn Arg Cys Gln Asp  
 65 70 75 80  
 Pro Asn Gly Gly Tyr Ala Gly Gly Pro Gly Gln Met Pro His Leu Ala  
 85 90 95  
 Thr Thr Tyr Ala Ala Val Asn Thr Leu Ile Thr Leu Gly Gly Glu Lys  
 100 105 110

**THIS PAGE BLANK (USPTO)**

Ser Leu Ala Ser Ile Asn Arg Asn Lys Leu Tyr Gly Phe Met Arg Arg  
 115 120 125  
 Met Lys Gln Pro Asn Gly Gly Phe Arg Met His Asp Glu Gly Glu Ile  
 130 135 140  
 Asp Val Arg Ala Cys Tyr Thr Ala Ile Ser Val Ala Ser Val Leu Asn  
 145 150 155 160  
 Ile Leu Asp Asp Glu Leu Ile Lys Asn Val Gly Asp Phe Ile Leu Ser  
 165 170 175  
 Cys Gln Thr Tyr Glu Gly Gly Leu Ala Gly Glu Pro Gly Ser Glu Ala  
 180 185 190  
 His Gly Gly Tyr Thr Phe Cys Gly Leu Ala Ala Met Ile Leu Ile Gly  
 195 200 205  
 Glu Val Asn Arg Leu Asp Leu Pro Arg Leu Leu Asp Trp Val Val Phe  
 210 215 220  
 Arg Gln Gly Lys Glu Cys Gly Phe Gln Gly Arg Thr Asn Lys Leu Val  
 225 230 235 240  
 Asp Gly Cys Tyr Ser Phe Trp Gln Gly Gly Ala Val Ala Leu Leu Gln  
 245 250 255  
 Arg Leu His Ser Ile Ile Asp Glu Gln Met Ala Glu Ala Ser Gln Phe  
 260 265 270  
 Val Thr Val Ser Asp Ala Pro Glu Glu Lys Glu Cys Leu Asp Gly Thr  
 275 280 285  
 Ser Ser His Ala Thr Ser His Ile Arg His Glu Gly Met Asn Glu Ser  
 290 295 300  
 Cys Ser Ser Asp Val Lys Asn Ile Gly Tyr Asn Phe Ile Ser Glu Trp  
 305 310 315 320  
 Arg Gln Ser Glu Pro Leu Phe His Ser Ile Ala Leu Gln Gln Tyr Ile  
 325 330 335  
 Leu Leu Cys Ser Gln Glu Gln Asp Gly Gly Leu Arg Asp Lys Pro Gly  
 340 345 350  
 Lys Arg Arg Asp His Tyr His Ser Cys Tyr Cys Leu Ser Gly Leu Ser  
 355 360 365  
 Leu Cys Gln Tyr Ser Trp Ser Lys Arg Pro Asp Ser Pro Pro Leu Pro  
 370 375 380  
 Lys Val Val Met Gly Pro Tyr Ser Asn Leu Leu Glu Pro Ile His Pro  
 385 390 395 400  
 Leu Phe Asn Val Val Leu Asp Arg Tyr Arg Glu Ala His Glu Phe Phe  
 405 410 415  
 Ser Gln Leu

**THIS PAGE BLANK (USPTO)**



# PATENT COOPERATION TREATY

## PCT

REC'D 13 DEC 2000

WIPO

PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>BB1240</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/US99/20419</b>	International filing date (day/month/year) <b>07/09/1999</b>	Priority date (day/month/year) <b>08/09/1998</b>
International Patent Classification (IPC) or national classification and IPC <b>C12N9/10</b>		
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>22/03/2000</b>	Date of completion of this report  <b>08.12.2000</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> <b>Tel. +49 89 2399 - 0 Tx: 523656 epmu d</b> <b>Fax: +49 89 2399 - 4465</b>	Authorized officer  <b>Morawetz, R</b>  <b>Telephone No. +49 89 2399 8155</b>



**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/20419

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

**Description, pages:**

1-24 as originally filed

**Claims, No.:**

1-31 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/20419

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

## IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:
- ☐ restricted the claims.
  - ☐ paid additional fees.
  - ☐ paid additional fees under protest.
  - ☒ neither restricted nor paid additional fees.
2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
  - ☒ not complied with for the following reasons:  
**see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☐ all parts.
  - ☒ the parts relating to claims Nos. 1-23, 28.

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims 1-7, 9, 10, 12-23, 28
	No:	Claims 8, 11
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-7, 9, 10, 12-23, 28
Industrial applicability (IA)	Yes:	Claims 1-23, 28
	No:	Claims

**THIS PAGE BLANK (USPTO)**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/20419

---

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**THIS PAGE BLANK (USPTO)**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/20419

**Re Item I**

**Basis of the report**

1. The applicant's attention is drawn to the fact that claims or part of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). Consequently, the subject-matter of claims 1 and 2 has only been examined insofar it has been searched (see PCT/ISA/210).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing (pages 1-22) filed together with the international application.

**Re Item IV**

**Lack of unity of invention**

1. The International Search Authority considered that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3 PCT).  
Four (groups of) inventions have been identified (see Form PCT/ISA/210)
  1. Claims 1-22 partly and 23, 28 completely
  2. Claims 1-22 partly and 24, 29 completely
  3. Claims 1-22 partly and 25, 26, 30, 31 completely
  4. Claims 1-22 partly and 27 completelyThe International Search Report covers all searchable claims.
2. The International Preliminary Examining Authority agreed with the International Search Authority regarding lack of unity of the international application and invited the applicant to indicate on which potential inventions identified and searched by the International Search Authority (see above) further examination should be based and either limit the claims and/or pay additional examination fees (Rule 68.2 PCT).
3. No response to this invitation has been received in due time, examination is, thus, based on the 1<sup>st</sup> potential invention (Article 34(3)(c) PCT).

**THIS PAGE BLANK (USPTO)**

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Reference is made to the following documents, the numbering corresponds to the listing of the documents in the international search report:

D1: QIAN ET AL., PLANT CELL, vol. 8, 1996, page 2381-2394

D2: YANG Z ET AL., PLANT PHYSIOLOGY, vol. 101, no. 2, 1993, page 667-674

D4: YALOVSKY S. ET AL., MOLECULAR AND CELLULAR BIOLOGY., vol. 17, no. 4, 1997, pages 1986-1994

D7: SKOCZYLAS E. ET AL., BIOCHIMIE, vol. 78, no. 2, 1996, pages 139-143

2. The present application does not satisfy the criterion set forth in **Article 33(2) PCT** because the subject-matter of claims 8 and 11 is not new in respect of prior art as defined in the regulations (**Rule 64(1)-(3) PCT**).

The present application relates to isolated polynucleotides (SEQ ID NO: 1, 11) which, based on homology with the known *Pisum sativum* and *Arabidopsis thaliana* protein farnesyltransferase (FTase) alpha and beta subunits, supposedly encode the homologous protein FTase subunits from corn (SEQ ID NO: 11, 12). The application as filed does, however, not contain any data regarding the expression or biological function of the putative FTase.

- 2.1. The subject-matter of claims 8 and 11 embraces any prior art isolated corn cell. Said claims are thus not considered novel.
- 2.2. The subject-matter of claims 1-7, 9, 10, 12-23 and 28 appears to be novel in view of the available prior art.
3. The present application does not satisfy the criterion set forth in **Article 33(3) PCT** because the subject-matter of claims 1-7, 9, 10, 12-23 and 28 does not involve an inventive step as defined in the regulations (**Rule 65 (1)-(2) PCT**).
- 3.1. The present application solves the problem of providing the FTase  $\alpha$  and  $\beta$

**THIS PAGE BLANK (USPTO)**

subunits from corn. FTases, however, are known from a variety of plants. The genes encoding the plant homologues of the FTase  $\alpha$  and  $\beta$  subunits have been cloned from pea (see D1, D2) and tomato (see D4) and D7 discloses (see Fig. 2) FTase activity in maize and wheat. It does not require inventive skill to use the available sequences and isolate the FTase  $\alpha$  and  $\beta$  subunits from yet another species, e.g. corn, from which no FTase had been isolated before. Claim 3 is consequently considered to lack inventive step.

- 3.2. Claims 1-2, 4-7, 9, 10, 12-23 and 28 concern embodiments which are familiar to the skilled person. Consequently, they would only be considered inventive if they were based upon a new and inventive nucleotide sequence. For the present claims this is not the case. Therefore the subject-matter of these claims is also considered to be obvious.

**Re Item VIII**

**Certain observations on the international application**

1. Article 6 PCT and Rule 6 PCT
  - 1.1. The feature "based on the Clustal method of alignment" in claims 1, 14 is considered unclear without an indication of the specific parameters used, i.e. gap penalty and gap length penalty.
  - 1.2. Claim 1 is also considered unclear because it is directed to polynucleotides of unknown function which need not retain any of the properties of the FTases to which they ultimately refer.
  - 1.3. The scope of claim 1 is furthermore rendered unclear by the vague terms "at least 300 amino acids" and "at least 80% identity".  
It is also unclear why claims 1, 23 and 28 refer to a first polypeptide and not just to a polypeptide (emphasis added).
  - 1.4. The feature "isolated" in connection with polynucleotide is not limiting the scope of claim 8, given that the polynucleotide is within the cell.
  - 1.5. The vague term "a substantial portion" used in claims 21, 22 is obscure and completely open to interpretation, rendering the scope of said claims unclear.

**THIS PAGE BLANK (USPTO)**

## PATENT COOPERATION TREATY

AGBIOTECH RECEIVED

MAY 23 2000

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

PATENT RECORDS  
CENTERNOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

To:

E.I. DU PONT DE NEMOURS AND COMPANY  
Legal/Patent Records Center  
Attn. MAJARIAN, William R.  
1007 Market Street  
Wilmington, Delaware 19898  
UNITED STATES OF AMERICA

Date of mailing  
(day/month/year)

15/05/2000

Applicant's or agent's file reference

BB1240

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 99/ 20419

International filing date  
(day/month/year)

07/09/1999

Applicant

E.I. DU PONT DE NEMOURS AND COMPANY et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

 European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Renate Jordan

CLS NOTED

5-31-2000  
MISP

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/PEA/401).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1240</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 20419</b>	International filing date (day/month/year) <b>07/09/1999</b>	(Earliest) Priority Date (day/month/year) <b>08/09/1998</b>
Applicant <b>E.I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/20419

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 2  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/20419

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/10 C12N15/29 C12N15/54 C12N15/70 C12N15/80

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X          A	QIAN ET AL: "Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control" PLANT CELL, vol. 8, 1996, page 2381-2394 XP002090873 ROCKVILLE US ISSN: 1040-4651 page 2390 -page 2392  ----- -/--	1,2,4, 6-8,10, 11,13,14         22, 24-26,29

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

26 April 2000

Date of mailing of the international search report

15. 5. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/20419

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YANG Z ET AL: "PROTEIN FARNESYLTRANSFERASE IN PLANTS 1 MOLECULAR CLONING AND EXPRESSION OF A HOMOLOG OF THE BETA SUBUNIT FROM THE GARDEN PEA" PLANT PHYSIOLOGY, vol. 101, no. 2, 1993, page 667-674 XP000647522 ROCKVILLE US ISSN: 0032-0889 cited in the application abstract; figure 2</p>	1-5, 22, 30
A	---	22, 31
A	<p>CUTLER S. ET AL: "A protein farnesyl transferase involved in abscisic acid signal transduction in arabidopsis" SCIENCE, vol. 273, August 1996 (1996-08), page 1239-1241 XP002090871 WASHINGTON US ISSN: 0036-8075</p>	1
A	<p>YALOVSKY S. ET AL.: "Plant farnesyl transferase can restore yeast ras signaling and mating" MOLECULAR AND CELLULAR BIOLOGY., vol. 17, no. 4, 1997, pages 1986-1994, XP000864327 WASHINGTON., US ISSN: 0270-7306 abstract</p>	1-5, 22, 27, 29
A	<p>HATA S. ET AL.: "cDNA cloning of squalene synthase genes from mono- and dicotyledonous plants, and expression of the gene in rice." PLANT AND CELL PHYSIOLOGY, vol. 38, no. 12, 1997, pages 1409-1413, XP000864329 abstract</p>	1
A	<p>MERLOT ET AL: "Genetic analysis of abscisic acid signal transduction" PLANT PHYSIOLOGY, vol. 114, 1997, page 751-757 XP002090872 ROCKVILLE US the whole document</p>	1
A	<p>SKOCZYLAS E. ET AL.: "Protein farnesyltransferase in plants" BIOCHIMIE, vol. 78, no. 2, 1996, pages 139-143, XP000864561 page 141, paragraph 2; figure 2</p>	1-5, 14, 22, 27

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-22 partly and 23, 28 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a corn farnesyltransferase polypeptide of SEQ.ID.NO: 2 or SEQ.ID.NO: 12; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a corn farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 1 or SEQ.ID.NO: 11.

2. Claims: 1-22 partly and 24, 29 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a rice farnesyltransferase polypeptide of SEQ.ID.NO: 4 or SEQ.ID.NO: 14; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a rice farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 3 or SEQ.ID.NO: 13.

3. Claims: 1-22 partly and 25, 26, 30, 31 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a soybean farnesyltransferase polypeptide of SEQ.ID.NO: 6,8,16 or 18; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

substantial portion of a soybean farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 5,7,15 or 17.

4. Claims: 1-22 partly and 27 completely

An isolated polynucleotide comprising a polynucleotide encoding a polypeptide of at least 300 amino acids, said polypeptide having at least 80 % identity with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a chimeric gene comprising said polynucleotide; a host cell comprising said polynucleotide; a virus comprising said polynucleotide; a farnesyltransferase polypeptide of at least 300 amino acids having at least 80% homology with a wheat farnesyltransferase polypeptide of SEQ.ID.NO: 10; a method of selecting an isolated polynucleotide that affects the level of a farnesyltransferase in a plant cell and a method of obtaining a nucleic acid fragment encoding a substantial portion of a wheat farnesyltransferase gene comprising using a primer derived from SEQ.ID.NO: 9.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 2

Claims 1 and 2 refer to a polynucleotide or the complement thereof, which encodes a polypeptide with a defined sequence.

Back-translation of the polypeptide generates a very large number of nucleic acid sequences. It is not possible to search for this enormous set of sequences. Therefore, the search has been restricted to the conventional nucleic acid/nucleic acid, protein/protein and protein/six-frame translated nucleic acid comparisons.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## PCT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C. 20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 10 May 2000 (10.05.00)	
International application No. PCT/US99/20419	Applicant's or agent's file reference BB1240
International filing date (day/month/year) 07 September 1999 (07.09.99)	Priority date (day/month/year) 08 September 1998 (08.09.98)
Applicant CAHOON, Rebecca, E. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 22 March 2000 (22.03.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer A. Karkachi Telephone No.: (41-22) 338.83.38
---	---

**THIS PAGE BLANK (USPTO)**